

TI Use of N-alkyl derivatives of 1,5-dideoxy-1,5-imino-D-glucitol for the  
 treatment of **hepatitis** B virus infections  
 IN Block, Timothy M.; Blumberg, Baruch S.; Dwek, Raymond A.  
 PA G.D. Searle and Co., USA; Monsanto Co.  
 SO PCT Int. Appl., 29 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K031-445  
 CC 1-5 (Pharmacology)  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9519172	A1	19950720	WO 1994-US14548	19941223
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ,				
VN	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2181033	AA	19950720	CA 1994-2181033	19941223
	AU 9514037	A1	19950801	AU 1995-14037	19941223
	EP 739205	A1	19961030	EP 1995-905416	19941223
	EP 739205	B1	19991124		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1149253	A	19970507	CN 1994-195049	19941223
	JP 09508111	T2	19970819	JP 1994-519024	19941223
	AT 186836	E	19991215	AT 1995-905416	19941223
	ES 2140652	T3	20000301	ES 1995-905416	19941223
	US 6037351	A	20000314	US 1996-676153	19960711
PRAI	US 1994-181519		19940113		
	WO 1994-US14548		19941223		
AB	A method is disclosed for the treatment of <b>hepatitis</b> B virus (HBV) infections, which comprises administering to the infected host an N-alkyl deriv. of 1,5-dideoxy-1,5-imido-D-glucitol in which the alkyl group contains from 3 to 6 carbon atoms. In examples, N-butyl-1,5-dideoxy-1,5-imino-D-glucitol was shown to suppress the secretion of HBV particles and to cause intracellular retention of HBV				
DNA	in both stably transfected HepG 2.2.15 cells and HBV-infected HepG 2 cells.				
ST	deoxynojirimycin deriv virucide <b>hepatitis</b> B				
IT	Virucides and Virustats (deoxynojirimycin alkyl derivs. for treatment of <b>hepatitis</b> B virus infections)				
IT	Virus, animal ( <b>hepatitis</b> B, deoxynojirimycin alkyl derivs. for treatment of <b>hepatitis</b> B virus infections)				
IT	72599-27-0, N-Butyl 1-deoxynojirimycin RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (deoxynojirimycin alkyl derivs. for treatment of <b>hepatitis</b> B virus infections)				

=>

TI Use of N-alkyl derivatives of 1,5-dideoxy-1,5-imino-D-glucitol for the  
 treatment of **hepatitis** B virus infections  
 IN Block, Timothy M.; Blumberg, Baruch S.; Dwek, Raymond A.  
 PA G.D. Searle and Co., USA; Monsanto Co.  
 SO PCT Int. Appl., 29 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K031-445  
 CC 1-5 (Pharmacology)  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9519172	A1	19950720	WO 1994-US14548	19941223
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ,				
VN	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2181033	AA	19950720	CA 1994-2181033	19941223
	AU 9514037	A1	19950801	AU 1995-14037	19941223
	EP 739205	A1	19961030	EP 1995-905416	19941223
	EP 739205	B1	19991124		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1149253	A	19970507	CN 1994-195049	19941223
	JP 09508111	T2	19970819	JP 1994-519024	19941223
	AT 186836	E	19991215	AT 1995-905416	19941223
	ES 2140652	T3	20000301	ES 1995-905416	19941223
	US 6037351	A	20000314	US 1996-676153	19960711
PRAI	US 1994-181519		19940113		
	WO 1994-US14548		19941223		
AB	A method is disclosed for the treatment of <b>hepatitis</b> B virus (HBV) infections, which comprises administering to the infected host an N-alkyl deriv. of 1,5-dideoxy-1,5-imido-D-glucitol in which the alkyl group contains from 3 to 6 carbon atoms. In examples, N-butyl-1,5-dideoxy-1,5-imino-D-glucitol was shown to suppress the secretion of HBV particles and to cause intracellular retention of HBV				
DNA	in both stably transfected HepG 2.2.15 cells and HBV-infected HepG 2 cells.				
ST	deoxynojirimycin deriv virucide <b>hepatitis</b> B				
IT	Virucides and Virustats (deoxynojirimycin alkyl derivs. for treatment of <b>hepatitis</b> B virus infections)				
IT	Virus, animal ( <b>hepatitis</b> B, deoxynojirimycin alkyl derivs. for treatment of <b>hepatitis</b> B virus infections)				
IT	72599-27-0, N-Butyl 1-deoxynojirimycin RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (deoxynojirimycin alkyl derivs. for treatment of <b>hepatitis</b> B virus infections)				

=>

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:sssptaul25rxt

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Dec 17 The CA Lexicon available in the CAPLUS and CA files  
NEWS 3 Feb 06 Engineering Information Encompass files have new names  
NEWS 4 Feb 16 TOXLINE no longer being updated  
NEWS 5 Apr 23 Search Derwent WPINDEX by chemical structure  
NEWS 6 Apr 23 PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA  
NEWS 7 May 07 DGENE Reload  
NEWS 8 Jun 20 Published patent applications (A1) are now in USPATFULL  
NEWS 9 JUL 13 New SDI alert frequency now available in Derwent's  
DWPI and DPCI  
NEWS 10 Aug 23 In-process records and more frequent updates now in  
MEDLINE  
NEWS 11 Aug 23 PAGE IMAGES FOR 1947-1966 RECORDS IN CAPLUS AND CA  
NEWS 12 Aug 23 Adis Newsletters (ADISNEWS) now available on STN  
NEWS 13 Sep 17 IMSworld Pharmaceutical Company Directory name change  
to PHARMASEARCH

NEWS EXPRESS August 15 CURRENT WINDOWS VERSION IS V6.0c,  
CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP),  
AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:59:11 ON 27 SEP 2001

=> FILE reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.15

0.15

FILE 'REGISTRY' ENTERED AT 11:59:22 ON 27 SEP 2001

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:sssptaul25rxt

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Dec 17 The CA Lexicon available in the CAPLUS and CA files  
NEWS 3 Feb 06 Engineering Information Encompass files have new names  
NEWS 4 Feb 16 TOXLINE no longer being updated  
NEWS 5 Apr 23 Search Derwent WPINDEX by chemical structure  
NEWS 6 Apr 23 PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA  
NEWS 7 May 07 DGENE Reload  
NEWS 8 Jun 20 Published patent applications (A1) are now in USPATFULL  
NEWS 9 JUL 13 New SDI alert frequency now available in Derwent's  
DWPI and DPCI  
NEWS 10 Aug 23 In-process records and more frequent updates now in  
MEDLINE  
NEWS 11 Aug 23 PAGE IMAGES FOR 1947-1966 RECORDS IN CAPLUS AND CA  
NEWS 12 Aug 23 Adis Newsletters (ADISNEWS) now available on STN  
NEWS 13 Sep 17 IMSworld Pharmaceutical Company Directory name change  
to PHARMASEARCH

NEWS EXPRESS August 15 CURRENT WINDOWS VERSION IS V6.0c,  
CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP),  
AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:59:11 ON 27 SEP 2001

=> FILE reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.15	0.15

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 11:59:22 ON 27 SEP 2001

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 26 SEP 2001 HIGHEST RN 358967-92-7  
DICTIONARY FILE UPDATES: 26 SEP 2001 HIGHEST RN 358967-92-7

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT  
for details.

=> e deoxynojirimycin

E1	32	DEOXYNOJIRI/BI
E2	1	DEOXYNOJIRIMICIN/BI
E3	32 -->	DEOXYNOJIRIMYCIN/BI
E4	1	DEOXYNOMININE/BI
E5	1	DEOXYNON/BI
E6	1	DEOXYNONA/BI
E7	1	DEOXYNONACTIC/BI
E8	1	DEOXYNONADECA/BI
E9	1	DEOXYNONON/BI
E10	1	DEOXYNONONAMIDE/BI
E11	3	DEOXYNONULO/BI
E12	3	DEOXYNONULOSON/BI

=> s e1-e3

	32	DEOXYNOJIRI/BI
	1	DEOXYNOJIRIMICIN/BI
	32	DEOXYNOJIRIMYCIN/BI
L1	32	(DEOXYNOJIRI/BI OR DEOXYNOJIRIMICIN/BI OR DEOXYNOJIRIMYCIN/BI)

=> s 3tc

L2	10	3TC
----	----	-----

=> d l2 10

L2 ANSWER 10 OF 10 REGISTRY COPYRIGHT 2001 ACS  
RN 12229-05-9 REGISTRY  
CN Hilgardite-3A (H2[Ca2(BO2)5Cl]) (9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Parahilgardite (7CI)  
OTHER NAMES:  
CN Hilgardite  
CN Hilgardite-3A  
CN **Hilgardite-3Tc**  
DR 12046-96-7  
MF B O2 . Ca . Cl . 2 H  
AF B5 Ca2 Cl O10 . 2 H  
CI MNS  
LC STN Files: CA, CAOLD, CAPLUS

CM 1

CRN 156286-03-2

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 26 SEP 2001 HIGHEST RN 358967-92-7  
DICTIONARY FILE UPDATES: 26 SEP 2001 HIGHEST RN 358967-92-7

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT  
for details.

=> e deoxynojirimycin

E1	32	DEOXYNOJIRI/BI
E2	1	DEOXYNOJIRIMICIN/BI
E3	32 -->	DEOXYNOJIRIMYCIN/BI
E4	1	DEOXYNOMININE/BI
E5	1	DEOXYNON/BI
E6	1	DEOXYNONA/BI
E7	1	DEOXYNONACTIC/BI
E8	1	DEOXYNONADECA/BI
E9	1	DEOXYNONON/BI
E10	1	DEOXYNONONAMIDE/BI
E11	3	DEOXYNONULO/BI
E12	3	DEOXYNONULOSON/BI

=> s e1-e3

	32	DEOXYNOJIRI/BI
	1	DEOXYNOJIRIMICIN/BI
	32	DEOXYNOJIRIMYCIN/BI
L1	32	(DEOXYNOJIRI/BI OR DEOXYNOJIRIMICIN/BI OR DEOXYNOJIRIMYCIN/BI)

=> s 3tc

L2	10	3TC
----	----	-----

=> d l2 10

L2 ANSWER 10 OF 10 REGISTRY COPYRIGHT 2001 ACS  
RN 12229-05-9 REGISTRY  
CN Hilgardite-3A (H2[Ca2(BO2)5Cl]) (9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Parahilgardite (7CI)  
OTHER NAMES:  
CN Hilgardite  
CN Hilgardite-3A  
CN **Hilgardite-3Tc**  
DR 12046-96-7  
MF B O2 . Ca . Cl . 2 H  
AF B5 Ca2 Cl O10 . 2 H  
CI MNS  
LC STN Files: CA, CAOLD, CAPLUS  
  
CM 1  
  
CRN 156286-03-2

CMF B O2 . Ca . Cl  
CCI TIS

CM 2

CRN 22537-15-1  
CMF Cl

Cl

CM 3

CRN 14100-65-3  
CMF B O2

$\text{O}=\text{B}=\text{O}$

CM 4

CRN 7440-70-2  
CMF Ca

Ca

7 REFERENCES IN FILE CA (1967 TO DATE)  
7 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> d 12 8

L2 ANSWER 8 OF 10 REGISTRY COPYRIGHT 2001 ACS

RN 134424-53-6 REGISTRY

CN Illite-3A

$([\text{Al}1.75(\text{Fe}0-1\text{Mg}0-1)0.25]\text{K}0.75(\text{Si}3.5\text{Al}0.5)[(\text{OH})0.5-1\text{F}0-0.5]2\text{O}10)$   
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN Guembelite

CN Hydromuscovite

CN Hydrosericite

CN Illidromica

CN Illite

CN Illite-3A

CN Illite-3T

CN **Illite-3Tc**

MF Al . F . Fe . H O . K . Mg . O5 Si2 . O

AF Al2.25 F0-1 Fe0-0.25 H1-2 K0.75 Mg0-0.25 O11-12 Si3.5

CI MNS, TIS

SR CA

LC STN Files: AGRICOLA, BIOBUSINESS, BIOSIS, CA, CAPLUS, CEN, CIN, PIRA,

CMF B O2 . Ca . Cl  
CCI TIS

CM 2

CRN 22537-15-1  
CMF Cl

Cl

CM 3

CRN 14100-65-3  
CMF B O2

$\text{^-O- B=O}$

CM 4

CRN 7440-70-2  
CMF Ca

Ca

7 REFERENCES IN FILE CA (1967 TO DATE)  
7 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> d 12 8

L2 ANSWER 8 OF 10 REGISTRY COPYRIGHT 2001 ACS

RN 134424-53-6 REGISTRY

CN Illite-3A

([Al1.75(Fe0-1Mg0-1)0.25]K0.75(Si3.5Al0.5)[(OH)0.5-1F0-0.5]2O10)  
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN Guembelite

CN Hydromuscovite

CN Hydrosericite

CN Illidromica

CN Illite

CN Illite-3A

CN Illite-3T

CN **Illite-3Tc**

MF Al . F . Fe . H O . K . Mg . O5 Si2 . O

AF Al2.25 F0-1 Fe0-0.25 H1-2 K0.75 Mg0-0.25 O11-12 Si3.5

CI MNS, TIS

SR CA

LC STN Files: AGRICOLA, BIOBUSINESS, BIOSIS, CA, CAPLUS, CEN, CIN, PIRA,



## TULSA

Component	Ratio	Component Registry Number
O5Si2	1.75	20328-07-8
O	1.25	17778-80-2
F	0 - 1	14762-94-8
HO	1 - 2	14280-30-9
K	0.75	7440-09-7
Mg	0 - 0.25	7439-95-4
Fe	0 - 0.25	7439-89-6
Al	2.25	7429-90-5

8 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=&gt; d 12 5

L2 ANSWER 5 OF 10 REGISTRY COPYRIGHT 2001 ACS

RN 178183-12-5 REGISTRY

CN Siderophyllite-3A ((Al2Si2)(Fe2Al)K[(OH)0.5-1F0-0.5]2O10) (9CI) (CA  
INDEX

NAME)

OTHER NAMES:

CN Siderophyllite

CN Siderophyllite-3A

CN **Siderophyllite-3Tc**

MF Al . F . Fe . H O . K . O4 Si . O

AF Al3 F0-1 Fe2 H1-2 K O11-12 Si2

CI MNS, TIS

SR CA

LC STN Files: CA, CAPLUS

Component	Ratio	Component Registry Number
O	2	17778-80-2
O4Si	2	17181-37-2
F	0 - 1	14762-94-8
HO	1 - 2	14280-30-9
K	1	7440-09-7
Fe	2	7439-89-6
Al	3	7429-90-5

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=&gt; file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

20.94

21.09

FILE 'CAPLUS' ENTERED AT 12:01:58 ON 27 SEP 2001

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

## TULSA

Component	Ratio	Component Registry Number
O5Si2	1.75	20328-07-8
O	1.25	17778-80-2
F	0 - 1	14762-94-8
HO	1 - 2	14280-30-9
K	0.75	7440-09-7
Mg	0 - 0.25	7439-95-4
Fe	0 - 0.25	7439-89-6
Al	2.25	7429-90-5

8 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=&gt; d 12 5

L2 ANSWER 5 OF 10 REGISTRY COPYRIGHT 2001 ACS

RN 178183-12-5 REGISTRY

CN Siderophyllite-3A ((Al2Si2)(Fe2Al)K[(OH)0.5-1F0-0.5]2O10) (9CI) (CA  
INDEX

NAME)

OTHER NAMES:

CN Siderophyllite

CN Siderophyllite-3A

CN **Siderophyllite-3Tc**

MF Al . F . Fe . H O . K . O4 Si . O

AF Al3 F0-1 Fe2 H1-2 K O11-12 Si2

CI MNS, TIS

SR CA

LC STN Files: CA, CAPLUS

Component	Ratio	Component Registry Number
O	2	17778-80-2
O4Si	2	17181-37-2
F	0 - 1	14762-94-8
HO	1 - 2	14280-30-9
K	1	7440-09-7
Fe	2	7439-89-6
Al	3	7429-90-5

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=&gt; file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

20.94

21.09

FILE 'CAPLUS' ENTERED AT 12:01:58 ON 27 SEP 2001

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 27 Sep 2001 VOL 135 ISS 14  
FILE LAST UPDATED: 26 Sep 2001 (20010926/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAPLUS now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

Attention, the CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

=> e hepatitis

E1	1	HEPATITIE/BI
E2	1	HEPATITIIS/BI
E3	31704	--> HEPATITIS/BI
E4	4	HEPATITISA/BI
E5	13	HEPATITISB/BI
E6	1	HEPATITISBX/BI
E7	9	HEPATITISC/BI
E8	1	HEPATITISG/BI
E9	1	HEPATITISRELATED/BI
E10	1	HEPATITISS/BI
E11	2	HEPATITISTHE/BI
E12	1	HEPATITISU/BI

=> s e3

L3 31704 HEPATITIS/BI

=> s hbv

L4 4491 HBV

=> s l1

L5 751 L1

=> s l2

L6 1070 L2

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 27 Sep 2001 VOL 135 ISS 14  
FILE LAST UPDATED: 26 Sep 2001 (20010926/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAPLUS now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

Attention, the CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

=> e hepatitis

E1	1	HEPATITIE/BI
E2	1	HEPATITIIS/BI
E3	31704 -->	HEPATITIS/BI
E4	4	HEPATITISA/BI
E5	13	HEPATITISB/BI
E6	1	HEPATITISBX/BI
E7	9	HEPATITISC/BI
E8	1	HEPATITISG/BI
E9	1	HEPATITISRELATED/BI
E10	1	HEPATITISS/BI
E11	2	HEPATITISTHE/BI
E12	1	HEPATITISU/BI

=> s e3

L3 31704 HEPATITIS/BI

=> s hbv

L4 4491 HBV

=> s l1

L5 751 L1

=> s l2

L6 1070 L2

=> s 15 and 16  
L7 16 L5 AND L6

=> d 17 1-16

L7 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2001 ACS  
AN 2001:617821 CAPLUS  
DN 135:175348  
TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for  
treating hepatitis virus infections  
IN Mueller, Richard A.; Bryant, Martin L.  
PA Pharmacia Corporation, USA  
SO PCT Int. Appl., 116 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001060366	A1	20010823	WO 2001-US4512	20010213
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				
	HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				
	LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				
	SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,				
	YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2000-182362	P	20000214		

RE.CNT 9  
RE

- (1) Block, T; NATURE MEDICINE 1998, V4(5), P610 CAPLUS
  - (2) Block, T; PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA 1994, V91(6), P2235 CAPLUS
  - (3) Dwek, R; WO 9835685 A 1998 CAPLUS
  - (4) Mueller, R; WO 9940916 A 1999 CAPLUS
  - (5) Mueller, R; WO 0047198 A 2000 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2001 ACS  
AN 2001:396644 CAPLUS  
DN 135:24671  
TI Solid carriers for improved delivery of active ingredients in  
pharmaceutical compositions  
IN Patel, Manesh V.; Chen, Feng-jing  
PA Lipocine, Inc., USA  
SO PCT Int. Appl., 107 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001037808	A1	20010531	WO 2000-US32255	20001122
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				

=> s 15 and 16  
L7 16 L5 AND L6

=> d 17 1-16

L7 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2001 ACS  
AN 2001:617821 CAPLUS  
DN 135:175348  
TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for  
treating hepatitis virus infections  
IN Mueller, Richard A.; Bryant, Martin L.  
PA Pharmacia Corporation, USA  
SO PCT Int. Appl., 116 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001060366	A1	20010823	WO 2001-US4512	20010213
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				
	HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				
	LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				
	SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,				
	YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2000-182362	P	20000214		

RE.CNT 9

RE

- (1) Block, T; NATURE MEDICINE 1998, V4(5), P610 CAPLUS
  - (2) Block, T; PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA 1994, V91(6), P2235 CAPLUS
  - (3) Dwek, R; WO 9835685 A 1998 CAPLUS
  - (4) Mueller, R; WO 9940916 A 1999 CAPLUS
  - (5) Mueller, R; WO 0047198 A 2000 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 2001:396644 CAPLUS

DN 135:24671

TI Solid carriers for improved delivery of active ingredients in  
pharmaceutical compositions

IN Patel, Manesh V.; Chen, Feng-jing

PA Lipocine, Inc., USA

SO PCT Int. Appl., 107 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001037808	A1	20010531	WO 2000-US32255	20001122
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				

HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,  
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,  
 ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 US 6248363 B1 20010619 US 1999-447690 19991123  
 PRAI US 1999-447690 A 19991123

RE.CNT 4  
 RE

- (1) Cho; US 4849227 A 1989 CAPLUS
- (2) Desieno; US 5573783 A 1996 CAPLUS
- (3) Harrison; US 4717569 A 1988 CAPLUS
- (4) Stetsko; US 5340589 A 1994 CAPLUS

L7 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 2001:338762 CAPLUS

DN 134:362292

TI Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile

IN Farr, Spencer

PA Phase-1 Molecular Toxicology, USA

SO PCT Int. Appl., 222 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001032928	A2	20010510	WO 2000-US30474	20001103
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				
	HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				
	LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				
	SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,				
	YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 1999-165398	P	19991105		
	US 2000-196571	P	20000411		

L7 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 2001:300514 CAPLUS

DN 134:331617

TI Oil-in-water emulsion compositions for polyfunctional active ingredients

IN Chen, Feng-jing; Patel, Mahesh V.

PA Lipocine, Inc., USA

SO PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001028555	A1	20010426	WO 2000-US28835	20001018
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,  
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,  
 ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 US 6248363 B1 20010619 US 1999-447690 19991123  
 PRAI US 1999-447690 A 19991123

RE.CNT 4

RE

- (1) Cho; US 4849227 A 1989 CAPLUS
- (2) Desieno; US 5573783 A 1996 CAPLUS
- (3) Harrison; US 4717569 A 1988 CAPLUS
- (4) Stetsko; US 5340589 A 1994 CAPLUS

L7 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 2001:338762 CAPLUS

DN 134:362292

TI Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile

IN Farr, Spencer

PA Phase-1 Molecular Toxicology, USA

SO PCT Int. Appl., 222 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001032928	A2	20010510	WO 2000-US30474	20001103
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 1999-165398	P	19991105		
	US 2000-196571	P	20000411		

L7 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 2001:300514 CAPLUS

DN 134:331617

TI Oil-in-water emulsion compositions for polyfunctional active ingredients

IN Chen, Feng-jing; Patel, Mahesh V.

PA Lipocine, Inc., USA

SO PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001028555	A1	20010426	WO 2000-US28835	20001018
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				



CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,  
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,  
 ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-420159 A 19991018

RE.CNT 6

RE

- (1) Bistrrian; US 4871768 A 1989 CAPLUS
- (2) Demichele; US 5661180 A 1997 CAPLUS
- (3) Demichele; US 6013665 A 2000 CAPLUS
- (4) Demichele; US 6130244 A 2000 CAPLUS
- (5) Demichele; US 6160007 A 2000 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 2001:137173 CAPLUS

DN 134:178396

TI Synthesis, activity and formulations of pharmaceutical compounds for  
 treatment of oxidative stress and/or endothelial dysfunction

IN Del Soldato, Piero

PA Nicox S.A., Fr.

SO PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2001012584	A2	20010222	WO 2000-EP7225	20000727
	W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GE, GD, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI IT 1999-MI1817 A 19990812

OS MARPAT 134:178396

L7 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 2001:114972 CAPLUS

DN 134:163282

TI Preparation of long chain N-alkyl amino and imino alditols and  
 oxa-derivatives as antiviral agents

IN Zitzmann, Nicole; Butters, Terry D.; Platt, Frances M.; Carrouee, Sandra;  
 Jacob, Gary S.; Picker, Donald H.; Fleet, George W. J.; Dwek, Raymond A.

PA UK

SO PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----

CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,  
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,  
 ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-420159 A 19991018

RE.CNT 6

RE

- (1) Bistrrian; US 4871768 A 1989 CAPLUS
- (2) Demichele; US 5661180 A 1997 CAPLUS
- (3) Demichele; US 6013665 A 2000 CAPLUS
- (4) Demichele; US 6130244 A 2000 CAPLUS
- (5) Demichele; US 6160007 A 2000 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 2001:137173 CAPLUS

DN 134:178396

TI Synthesis, activity and formulations of pharmaceutical compounds for  
 treatment of oxidative stress and/or endothelial dysfunction

IN Del Soldato, Piero

PA Nicox S.A., Fr.

SO PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2001012584	A2	20010222	WO 2000-EP7225	20000727
	W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE,				
	HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG,				
	MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN,				
	YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,				
	CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI IT 1999-MI1817 A 19990812

OS MARPAT 134:178396

L7 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 2001:114972 CAPLUS

DN 134:163282

TI Preparation of long chain N-alkyl amino and imino alditols and  
 oxa-derivatives as antiviral agents

IN Zitzmann, Nicole; Butters, Terry D.; Platt, Frances M.; Carrouee, Sandra;  
 Jacob, Gary S.; Picker, Donald H.; Fleet, George W. J.; Dwek, Raymond A.

PA UK

SO PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----

PI WO 2001010429 A2 20010215 WO 2000-US21732 20000810  
 WO 2001010429 A3 20010816  
 W: AU, BR, CA, CN, IN, JP, KR, US  
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,  
 PT, SE  
 AU 2001018401 A5 20010305 AU 2001-18401 20000810  
 PRAI US 1999-148101 P 19990810  
 US 2000-198621 P 20000420  
 WO 2000-US21732 W 20000810  
 OS MARPAT 134:163282

L7 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2001 ACS  
 AN 2001:100967 CAPLUS  
 DN 134:141721  
 TI N-Substituted glucamine compounds for treating hepatitis virus infections  
 IN Mueller, Richard A.; Bryant, Martin L.; Partis, Richard A.  
 PA G.D. Searle & Co., USA  
 SO PCT Int. Appl., 148 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001008672	A2	20010208	WO 2000-US3816	20000214
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 1999-119836	P	19990212		
	US 1999-119858	P	19990212		
OS	MARPAT 134:141721				

L7 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2001 ACS  
 AN 2000:861473 CAPLUS  
 DN 134:32972  
 TI Porous drug matrixes containing polymers and sugars and methods of their manufacture  
 IN Straub, Julie; Bernstein, Howard; Chickering, Donald E., III; Khatak, Sarwat; Randall, Greg  
 PA Acusphere, Inc., USA  
 SO PCT Int. Appl., 45 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000072827	A2	20001207	WO 2000-US14578	20000525
	WO 2000072827	A3	20010125		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,			

PI WO 2001010429 A2 20010215 WO 2000-US21732 20000810  
 WO 2001010429 A3 20010816  
 W: AU, BR, CA, CN, IN, JP, KR, US  
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,  
 PT, SE  
 AU 2001018401 A5 20010305 AU 2001-18401 20000810  
 PRAI US 1999-148101 P 19990810  
 US 2000-198621 P 20000420  
 WO 2000-US21732 W 20000810  
 OS MARPAT 134:163282

L7 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2001 ACS  
 AN 2001:100967 CAPLUS  
 DN 134:141721  
 TI N-Substituted glucamine compounds for treating hepatitis virus infections  
 IN Mueller, Richard A.; Bryant, Martin L.; Partis, Richard A.  
 PA G.D. Searle & Co., USA  
 SO PCT Int. Appl., 148 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001008672	A2	20010208	WO 2000-US3816	20000214
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 1999-119836	P	19990212		
	US 1999-119858	P	19990212		
OS	MARPAT 134:141721				

L7 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2001 ACS  
 AN 2000:861473 CAPLUS  
 DN 134:32972  
 TI Porous drug matrixes containing polymers and sugars and methods of their manufacture  
 IN Straub, Julie; Bernstein, Howard; Chickering, Donald E., III; Khatak, Sarwat; Randall, Greg  
 PA Acusphere, Inc., USA  
 SO PCT Int. Appl., 45 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000072827	A2	20001207	WO 2000-US14578	20000525
	WO 2000072827	A3	20010125		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,				

MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,  
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-136323 P 19990527  
 US 1999-158659 P 19991008  
 US 1999-433486 A 19991104  
 US 2000-186310 P 20000302

L7 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2001 ACS  
 AN 2000:742057 CAPLUS  
 DN 133:309791  
 TI Synthesis, activity and formulations of pharmaceutical compounds for  
 treatment of oxidative stress and/or endothelial dysfunction  
 IN Del Soldato, Piero  
 PA Nicox S.A., Fr.  
 SO PCT Int. Appl., 140 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000061541	A2	20001019	WO 2000-EP3239	20000411
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DM, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	IT 1999-MI752	A	19990413		
OS	MARPAT 133:309791				

L7 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2001 ACS  
 AN 2000:742053 CAPLUS  
 DN 133:310142  
 TI Synthesis, activity and formulations of pharmaceutical compounds for  
 treatment of oxidative stress and/or endothelial dysfunction  
 IN Del Soldato, Piero  
 PA Nicox S.A., Fr.  
 SO PCT Int. Appl., 159 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000061537	A2	20001019	WO 2000-EP3234	20000411
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DM, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,  
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-136323 P 19990527  
 US 1999-158659 P 19991008  
 US 1999-433486 A 19991104  
 US 2000-186310 P 20000302

L7 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 2000:742057 CAPLUS

DN 133:309791

TI Synthesis, activity and formulations of pharmaceutical compounds for  
 treatment of oxidative stress and/or endothelial dysfunction

IN Del Soldato, Piero

PA Nicox S.A., Fr.

SO PCT Int. Appl., 140 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000061541	A2	20001019	WO 2000-EP3239	20000411
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DM, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI IT 1999-MI752 A 19990413

OS MARPAT 133:309791

L7 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 2000:742053 CAPLUS

DN 133:310142

TI Synthesis, activity and formulations of pharmaceutical compounds for  
 treatment of oxidative stress and/or endothelial dysfunction

IN Del Soldato, Piero

PA Nicox S.A., Fr.

SO PCT Int. Appl., 159 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000061537	A2	20001019	WO 2000-EP3234	20000411
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DM, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI IT 1999-MI753 A 19990413  
OS MARPAT 133:310142

L7 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2001 ACS  
AN 2000:725436 CAPLUS  
DN 133:301171  
TI Compositions and methods for improved delivery of ionizable hydrophobic  
therapeutic agents  
IN Chen, Feng-jing; Patel, Manesh V.  
PA Lipocine, Inc., USA  
SO PCT Int. Appl., 99 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000059475	A1	20001012	WO 2000-US7342	20000316
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRAI US 1999-287043 A 19990406

RE.CNT 3

RE

- (1) Blair; US 4306981 A 1981 CAPLUS
- (2) Hauer; US 5342625 A 1994 CAPLUS
- (3) Story; US 4944949 A 1990 CAPLUS

L7 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2001 ACS  
AN 2000:573657 CAPLUS  
DN 133:172150  
TI Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for  
treating

hepatitis virus infections  
IN Mueller, Richard A.; Bryant, Martin L.; Partis, Richard A.  
PA G.D. Searle & Co., USA  
SO PCT Int. Appl., 170 pp.  
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000047198	A2	20000817	WO 2000-US3768	20000214
	WO 2000047198	A3	20010215		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,			

PRAI IT 1999-MI753 A 19990413  
OS MARPAT 133:310142

L7 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2001 ACS  
AN 2000:725436 CAPLUS  
DN 133:301171  
TI Compositions and methods for improved delivery of ionizable hydrophobic  
therapeutic agents  
IN Chen, Feng-jing; Patel, Manesh V.  
PA Lipocine, Inc., USA  
SO PCT Int. Appl., 99 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000059475	A1	20001012	WO 2000-US7342	20000316
	W:				
	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,				
	CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,				
	IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,				
	MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG,				
	SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM,				
	AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,				
	DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,				
	CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI US 1999-287043 A 19990406

RE.CNT 3

RE

- (1) Blair; US 4306981 A 1981 CAPLUS
- (2) Hauer; US 5342625 A 1994 CAPLUS
- (3) Story; US 4944949 A 1990 CAPLUS

L7 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2001 ACS  
AN 2000:573657 CAPLUS  
DN 133:172150  
TI Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for  
treating

hepatitis virus infections  
IN Mueller, Richard A.; Bryant, Martin L.; Partis, Richard A.  
PA G.D. Searle & Co., USA  
SO PCT Int. Appl., 170 pp.  
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000047198	A2	20000817	WO 2000-US3768	20000214
	WO 2000047198	A3	20010215		
	W:				
	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,				
	CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,				
	IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,				
	MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,				
	SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,				
	AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,				



DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-119722 P 19990212  
US 1999-119856 P 19990212

OS MARPAT 133:172150

L7 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2001 ACS  
AN 1999:529023 CAPLUS  
DN 131:165293  
TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for  
treating hepatitis virus infections  
IN Mueller, Richard A.; Bryant, Martin L.; Partis, Richard A.  
PA G.D. Searle & Co., USA  
SO PCT Int. Appl., 138 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9940916	A1	19990819	WO 1999-US1874	19990212
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9927595	A1	19990830	AU 1999-27595	19990212
	BR 9907882	A	20001017	BR 1999-7882	19990212
	EP 1061922	A1	20001227	EP 1999-908079	19990212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
FI					
PRAI	US 1998-23401	A	19980212		
	US 1998-74508	P	19980212		
	WO 1999-US1874	W	19990212		

OS MARPAT 131:165293

RE.CNT 9

RE

- (1) Bayer AG; EP 0449026 A 1991 CAPLUS
  - (3) G D Searle & Co; WO 9522975 A 1995 CAPLUS
  - (4) G D Searle & Co; EP 0367748 A 1990 CAPLUS
  - (5) G D Searle and Co; WO 9835685 A 1998 CAPLUS
  - (6) Meiji Seika Kaisha Ltd; EP 0350012 A 1990 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2001 ACS  
AN 1998:568726 CAPLUS  
DN 129:197981  
TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in  
combination therapy for treating hepatitis virus infections  
IN Jacob, Gary S.; Block, Timothy M.; Dwek, Raymond A.  
PA G.D. Searle and Co., USA  
SO PCT Int. Appl., 74 pp.  
CODEN: PIXXD2  
DT Patent

DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-119722 P 19990212  
US 1999-119856 P 19990212

OS MARPAT 133:172150

L7 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2001 ACS  
AN 1999:529023 CAPLUS  
DN 131:165293  
TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for  
treating hepatitis virus infections  
IN Mueller, Richard A.; Bryant, Martin L.; Partis, Richard A.  
PA G.D. Searle & Co., USA  
SO PCT Int. Appl., 138 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9940916	A1	19990819	WO 1999-US1874	19990212
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9927595	A1	19990830	AU 1999-27595	19990212
	BR 9907882	A	20001017	BR 1999-7882	19990212
	EP 1061922	A1	20001227	EP 1999-908079	19990212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				

FI

PRAI US 1998-23401 A 19980212  
US 1998-74508 P 19980212  
WO 1999-US1874 W 19990212

OS MARPAT 131:165293

RE.CNT 9

RE

- (1) Bayer AG; EP 0449026 A 1991 CAPLUS
- (3) G D Searle & Co; WO 9522975 A 1995 CAPLUS
- (4) G D Searle & Co; EP 0367748 A 1990 CAPLUS
- (5) G D Searle and Co; WO 9835685 A 1998 CAPLUS
- (6) Meiji Seika Kaisha Ltd; EP 0350012 A 1990 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2001 ACS  
AN 1998:568726 CAPLUS  
DN 129:197981  
TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in  
combination therapy for treating hepatitis virus infections  
IN Jacob, Gary S.; Block, Timothy M.; Dwek, Raymond A.  
PA G.D. Searle and Co., USA  
SO PCT Int. Appl., 74 pp.  
CODEN: PIXXD2  
DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9835685	A1	19980820	WO 1998-US3004	19980212
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9861692	A1	19980908	AU 1998-61692	19980212
	EP 1007058	A1	20000614	EP 1998-906475	19980212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
FI	JP 2001512462	T2	20010821	JP 1998-535987	19980212
PRAI	US 1997-41221	P	19970214		
	WO 1998-US3004	W	19980212		
OS	MARPAT 129:197981				

L7 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 1998:331371 CAPLUS

DN 129:16395

TI Preparation of phenylstatine derivatives as retroviral protease inhibitors

IN Chang, Min S.; Getman, Daniel P.; Mueller, Richard A.; Ottinger, James C.;

Stolzenbach, James C.; Talley, John J.; Vazquez, Michael L.; Decrescenzo, Gary A.

PA G. D. Searle & Co., USA

SO U.S., 20 pp. Cont.-in-part of U.S. Ser. No. 109,787, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5750648	A	19980512	US 1994-253531	19940603
	WO 9506061	A1	19950302	WO 1994-US8697	19940809
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ,				
VN	RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD,				
TG	AU 9475186	A1	19950321	AU 1994-75186	19940809
	ZA 9406325	A	19950821	ZA 1994-6325	19940819
	IL 110724	A1	19990817	IL 1994-110724	19940819
PRAI	US 1993-109787		19930820		
	US 1994-253531		19940603		
	WO 1994-US8697		19940809		
OS	MARPAT 129:16395				

L7 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 1994:153741 CAPLUS

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9835685	A1	19980820	WO 1998-US3004	19980212
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9861692	A1	19980908	AU 1998-61692	19980212
	EP 1007058	A1	20000614	EP 1998-906475	19980212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
FI	JP 2001512462	T2	20010821	JP 1998-535987	19980212
PRAI	US 1997-41221	P	19970214		
	WO 1998-US3004	W	19980212		
OS	MARPAT 129:197981				

L7 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 1998:331371 CAPLUS

DN 129:16395

TI Preparation of phenylstatine derivatives as retroviral protease inhibitors

IN Chang, Min S.; Getman, Daniel P.; Mueller, Richard A.; Ottinger, James C.;

Stolzenbach, James C.; Talley, John J.; Vazquez, Michael L.; Decrescenzo, Gary A.

PA G. D. Searle & Co., USA

SO U.S., 20 pp. Cont.-in-part of U.S. Ser. No. 109,787, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5750648	A	19980512	US 1994-253531	19940603
	WO 9506061	A1	19950302	WO 1994-US8697	19940809
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ,				
VN					
	RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD,				
TG					
	AU 9475186	A1	19950321	AU 1994-75186	19940809
	ZA 9406325	A	19950821	ZA 1994-6325	19940819
	IL 110724	A1	19990817	IL 1994-110724	19940819
PRAI	US 1993-109787		19930820		
	US 1994-253531		19940603		
	WO 1994-US8697		19940809		
OS	MARPAT 129:16395				

L7 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 1994:153741 CAPLUS

DN 120:153741  
 TI Use of antiretroviral drugs for treatment of motor neuron diseases  
 IN Westarp, Martin Egon; Kornhuber, Hans Helmut  
 PA Germany  
 SO Ger. Offen., 6 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4307883	A1	19930923	DE 1993-4307883	19930312
PRAI	DE 1992-4207863		19920312		

=> d 17 14 15 16 all

L7 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2001 ACS  
 AN 1998:568726 CAPLUS  
 DN 129:197981  
 TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination therapy for treating hepatitis virus infections  
 IN Jacob, Gary S.; Block, Timothy M.; Dwek, Raymond A.  
 PA G.D. Searle and Co., USA  
 SO PCT Int. Appl., 74 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K031-70  
 ICS A61K031-70; A61K031-445  
 CC 1-5 (Pharmacology)  
 Section cross-reference(s): 33, 63  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9835685	A1	19980820	WO 1998-US3004	19980212
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9861692	A1	19980908	AU 1998-61692	19980212
	EP 1007058	A1	20000614	EP 1998-906475	19980212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
FI	JP 2001512462	T2	20010821	JP 1998-535987	19980212
PRAI	US 1997-41221	P	19970214		
	WO 1998-US3004	W	19980212		
OS	MARPAT 129:197981				

AB Methods and compns. are provided for treating hepatitis virus infections in mammals, esp. humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compds. in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixts. thereof, or immunomodulating/immunostimulating agents, or (2) administering

DN 120:153741  
 TI Use of antiretroviral drugs for treatment of motor neuron diseases  
 IN Westarp, Martin Egon; Kornhuber, Hans Helmut  
 PA Germany  
 SO Ger. Offen., 6 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4307883	A1	19930923	DE 1993-4307883	19930312
PRAI	DE 1992-4207863		19920312		

=> d 17 14 15 16 all

L7 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2001 ACS  
 AN 1998:568726 CAPLUS  
 DN 129:197981  
 TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in  
 combination therapy for treating hepatitis virus infections  
 IN Jacob, Gary S.; Block, Timothy M.; Dwek, Raymond A.  
 PA G.D. Searle and Co., USA  
 SO PCT Int. Appl., 74 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K031-70  
 ICS A61K031-70; A61K031-445  
 CC 1-5 (Pharmacology)  
 Section cross-reference(s): 33, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9835685	A1	19980820	WO 1998-US3004	19980212
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9861692	A1	19980908	AU 1998-61692	19980212
	EP 1007058	A1	20000614	EP 1998-906475	19980212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
FI	JP 2001512462	T2	20010821	JP 1998-535987	19980212
PRAI	US 1997-41221	P	19970214		
	WO 1998-US3004	W	19980212		
OS	MARPAT 129:197981				
AB	Methods and compns. are provided for treating hepatitis virus infections in mammals, esp. humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compds. in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixts. thereof, or immunomodulating/immunostimulating agents, or (2) administering				

N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compds. in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixts. thereof, and immunomodulating/immunostimulating agents. Prepn. of 1,5-(butylimino)-1,5-dideoxy-D-glucitol and of the corresponding tetraacetate is described.

ST dideoxyiminoglucitol deriv antiviral hepatitis virus; tetraacetate butyliminodideoxyglucitol prepn antiviral hepatitis virus; nucleoside dideoxyiminoglucitol deriv antiviral combination hepatitis; nucleotide dideoxyiminoglucitol deriv antiviral combination hepatitis; immunomodulator dideoxyiminoglucitol deriv antiviral combination hepatitis; immunostimulant dideoxyiminoglucitol deriv antiviral combination hepatitis

IT Nucleotides, biological studies  
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (analogs, antiviral; dideoxyiminoglucitol derivs. in combination therapy for treating hepatitis virus infections)

IT Nucleoside analogs  
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (antiviral; dideoxyiminoglucitol derivs. in combination therapy for treating hepatitis virus infections)

IT Antiviral agents  
 Drug delivery systems  
 Drug interactions  
 Hepatitis B virus  
 Hepatitis virus  
 (dideoxyiminoglucitol derivs. in combination therapy for treating hepatitis virus infections)

IT 3056-17-5, Stavudine 7481-89-2, Dideoxycytidine **19130-96-2D**, 1,5-Dideoxy-1,5-imino-D-glucitol, N-substituted derivs. 25526-93-6 30516-87-1, AZT 36791-04-5 66341-18-2, Acyclovir triphosphate 69123-90-6, FIAC 69256-17-3 69655-05-6, Dideoxyinosine 72458-45-8 **72458-46-9** 73243-67-1 79206-10-3 **79206-12-5** 79206-20-5 79206-22-7 80860-82-8 **81117-34-2** 81117-35-3 81117-38-6 85326-06-3 87190-81-6 99876-43-4 106941-25-7, 9-(2-Phosphonylmethoxyethyl)adenine 111687-37-7, D-Carbocyclic-2'-deoxyguanosine 115249-95-1 121154-51-6 128985-11-5 131167-83-4 **134678-17-4**, 3TC 134680-32-3 137530-41-7 143491-54-7, FTC 147058-39-7 160963-03-1 211987-28-9 211987-29-0 211987-30-3 211987-31-4 211987-32-5 211987-33-6 211987-34-7 211987-35-8 211987-36-9 211987-37-0 211987-38-1 211987-39-2 211987-40-5 211987-41-6 211987-42-7 211987-43-8 211987-44-9 211987-45-0 211987-46-1 211987-47-2 211987-48-3 211987-49-4 211987-50-7 211987-51-8 211987-52-9 211987-53-0 211987-54-1 211987-55-2 211987-56-3 211987-57-4 211987-58-5 211987-59-6 211987-60-9 211987-61-0 211987-62-1  
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (dideoxyiminoglucitol derivs. in combination therapy for treating hepatitis virus infections)

IT **72599-27-0P**  
 RL: BAC (Biological activity or effector, except adverse); RCT (Reactant);  
 SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (dideoxyiminoglucitol derivs. in combination therapy for treating

N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compds. in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixts. thereof, and immunomodulating/immunostimulating agents. Prepn. of 1,5-(butylimino)-1,5-dideoxy-D-glucitol and of the corresponding tetraacetate is described.

ST dideoxyiminoglucitol deriv antiviral hepatitis virus; tetraacetate butyliminodideoxyglucitol prepn antiviral hepatitis virus; nucleoside dideoxyiminoglucitol deriv antiviral combination hepatitis; nucleotide dideoxyiminoglucitol deriv antiviral combination hepatitis; immunomodulator dideoxyiminoglucitol deriv antiviral combination hepatitis; immunostimulant dideoxyiminoglucitol deriv antiviral combination hepatitis

IT Nucleotides, biological studies  
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (analogs, antiviral; dideoxyiminoglucitol derivs. in combination therapy for treating hepatitis virus infections)

IT Nucleoside analogs  
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (antiviral; dideoxyiminoglucitol derivs. in combination therapy for treating hepatitis virus infections)

IT Antiviral agents  
 Drug delivery systems  
 Drug interactions  
 Hepatitis B virus  
 Hepatitis virus  
 (dideoxyiminoglucitol derivs. in combination therapy for treating hepatitis virus infections)

IT 3056-17-5, Stavudine 7481-89-2, Dideoxycytidine **19130-96-2D**, 1,5-Dideoxy-1,5-imino-D-glucitol, N-substituted derivs. 25526-93-6 30516-87-1, AZT 36791-04-5 66341-18-2, Acyclovir triphosphate 69123-90-6, FIAC 69256-17-3 69655-05-6, Dideoxyinosine 72458-45-8 **72458-46-9** 73243-67-1 79206-10-3 **79206-12-5** 79206-20-5 79206-22-7 80860-82-8 **81117-34-2** 81117-35-3 81117-38-6 85326-06-3 87190-81-6 99876-43-4 106941-25-7, 9-(2-Phosphonylmethoxyethyl)adenine 111687-37-7, D-Carbocyclic-2'-deoxyguanosine 115249-95-1 121154-51-6 128985-11-5 131167-83-4 **134678-17-4**, 3TC 134680-32-3 137530-41-7 143491-54-7, FTC 147058-39-7 160963-03-1 211987-28-9 211987-29-0 211987-30-3 211987-31-4 211987-32-5 211987-33-6 211987-34-7 211987-35-8 211987-36-9 211987-37-0 211987-38-1 211987-39-2 211987-40-5 211987-41-6 211987-42-7 211987-43-8 211987-44-9 211987-45-0 211987-46-1 211987-47-2 211987-48-3 211987-49-4 211987-50-7 211987-51-8 211987-52-9 211987-53-0 211987-54-1 211987-55-2 211987-56-3 211987-57-4 211987-58-5 211987-59-6 211987-60-9 211987-61-0 211987-62-1  
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (dideoxyiminoglucitol derivs. in combination therapy for treating hepatitis virus infections)

IT **72599-27-0P**  
 RL: BAC (Biological activity or effector, except adverse); RCT (Reactant);  
 SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (dideoxyiminoglucitol derivs. in combination therapy for treating



hepatitis virus infections, and deriv. prepn.)  
 IT 131262-77-6P  
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (dideoxyiminoglucitol derivs. in combination therapy for treating hepatitis virus infections, and deriv. prepn.)  
 IT 108-24-7, Acetic anhydride 123-72-8, Butyraldehyde **19130-96-2**, 1,5-Dideoxy-1,5-imino-D-glucitol  
 RL: RCT (Reactant)  
 (reaction; dideoxyiminoglucitol derivs. in combination therapy for treating hepatitis virus infections, and deriv. prepn.)

L7 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 1998:331371 CAPLUS

DN 129:16395

TI Preparation of phenylstatine derivatives as retroviral protease inhibitors

IN Chang, Min S.; Getman, Daniel P.; Mueller, Richard A.; Ottinger, James C.;

; Talley, John J.; Vazquez, Michael L.; Decrescenzo,

PI 5,750,648  
 SC USA

-part of U.S. Ser. No. 109,787, abandoned.

DT DE 4307883  
 LA  
 IC  
 NCI  
 CC A11930923

CC (Nucleosides, Nucleotides, Peptides, and Proteins)

Section cross-reference(s): 1

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5750648	A	19980512	US 1994-253531	19940603
	WO 9506061	A1	19950302	WO 1994-US8697	19940809
	W:	AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ,			
VN		RW:	KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD,		
TG	AU 9475186	A1	19950321	AU 1994-75186	19940809
	ZA 9406325	A	19950821	ZA 1994-6325	19940819
	IL 110724	A1	19990817	IL 1994-110724	19940819
PRAI	US 1993-109787		19930820		
	US 1994-253531		19940603		
	WO 1994-US8697		19940809		
OS	MARPAT 129:16395				
GI					

hepatitis virus infections, and deriv. prepn.)  
 IT 131262-77-6P  
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (dideoxyiminoglucitol derivs. in combination therapy for treating hepatitis virus infections, and deriv. prepn.)  
 IT 108-24-7, Acetic anhydride 123-72-8, Butyraldehyde **19130-96-2**, 1,5-Dideoxy-1,5-imino-D-glucitol  
 RL: RCT (Reactant)  
 (reaction; dideoxyiminoglucitol derivs. in combination therapy for treating hepatitis virus infections, and deriv. prepn.)

L7 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 1998:331371 CAPLUS

DN 129:16395

TI Preparation of phenylstatine derivatives as retroviral protease inhibitors

IN Chang, Min S.; Getman, Daniel P.; Mueller, Richard A.; Ottinger, James C.;

Stolzenbach, James C.; Talley, John J.; Vazquez, Michael L.; Decrescenzo, Gary A.

PA G. D. Searle & Co., USA

SO U.S., 20 pp. Cont.-in-part of U.S. Ser. No. 109,787, abandoned.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K038-06


NCL 530331000

CC 34-3 (Amino Acids, Peptides, and Proteins)

Section cross-reference(s): 1

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5750648	A	19980512	US 1994-253531	19940603
	WO 9506061	A1	19950302	WO 1994-US8697	19940809
	W:	AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ,			
VN		RW:	KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD,		
TG	AU 9475186	A1	19950321	AU 1994-75186	19940809
	ZA 9406325	A	19950821	ZA 1994-6325	19940819
	IL 110724	A1	19990817	IL 1994-110724	19940819
PRAI	US 1993-109787		19930820		
	US 1994-253531		19940603		
	WO 1994-US8697		19940809		
OS	MARPAT 129:16395				
GI					



AB The present invention is directed to the prepn. and use of retroviral protease inhibitors I [R1 = CHMe2, CHMeEt, CMe3, CMe2SMe, CMe2S(O)Me, CMe2SO2Me; R2 = Me-L-Ala, Me-D-Ala, H-Gly, Me-Gly, H-L-Pro, H-D-Pro, H-L-Ile each optionally substituted on the nitrogen atom with benzyloxycarbonyl or tert-butoxycarbonyl], or a pharmaceutically acceptable salt or ester thereof, and combinations of retroviral protease inhibitors which are effective in preventing the replication of mammalian retroviruses, such as human immunodeficiency virus (HIV). Thus, coupling of N-benzyloxycarbonyl-N-methyl-L-alanine with reduced peptide mimic I

(R1 = CMe3; R2 = H) (prepd. in 7 steps from N-benzyloxycarbonyl-L-phenylalanine chloromethyl ketone, isoamylamine, tert-Bu isocyanate, and N-benzyloxycarbonyl-L-tert-butylglycine), followed by catalytic deprotection, gave 54% desired inhibitor I (R1 = CMe3, R2 = Me-L-Ala) (II). II inhibited HIV-infected cells with IC50 = 8 nM, and EC50 = 96 mg/mL in the presence of AZT or DDI.

ST phenylstatine deriv prepn retroviral protease inhibitor; reduced phenylalanine peptide prepn HIV inhibitor

IT Anti-AIDS drugs

Antiviral agents

Human immunodeficiency virus 1

(prepn. of phenylstatine derivs. as retroviral protease inhibitors)

IT 168056-64-2P 168056-65-3P 168056-66-4P 168056-68-6P 168056-69-7P  
168112-86-5P

RL: BAC (Biological activity or effector, except adverse); RCT

(Reactant);

SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of phenylstatine derivs. as retroviral protease inhibitors)

IT 143577-34-8P 155662-50-3P 159910-86-8P 168056-54-0P 168056-55-1P  
168056-56-2P 168056-57-3P 168056-58-4P 168056-59-5P 168056-60-8P  
168056-61-9P 168056-62-0P 168056-63-1P 168056-67-5P 168056-70-0P  
168112-84-3P 168112-85-4P 168112-87-6P 207614-10-6P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of phenylstatine derivs. as retroviral protease inhibitors)

IT 7481-89-2, DDC 23339-47-1, DAT 30516-87-1, AZT 69655-05-6, DDI  
**72599-27-0**, N-Butyl-1-deoxynojirimycin 79831-76-8,  
Castanospermine 106941-25-7, PME A **134678-17-4**, 3TC


RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(prepn. of phenylstatine derivs. as retroviral protease inhibitors)

IT 127943-39-9P

RL: BYP (Byproduct); PREP (Preparation)

(prepn. of phenylstatine derivs. as retroviral protease inhibitors)



AB The present invention is directed to the prepn. and use of retroviral protease inhibitors I [R1 = CHMe2, CHMeEt, CMe3, CMe2SMe, CMe2S(O)Me, CMe2SO2Me; R2 = Me-L-Ala, Me-D-Ala, H-Gly, Me-Gly, H-L-Pro, H-D-Pro, H-L-Ile each optionally substituted on the nitrogen atom with benzyloxycarbonyl or tert-butoxycarbonyl], or a pharmaceutically acceptable salt or ester thereof, and combinations of retroviral protease inhibitors which are effective in preventing the replication of mammalian retroviruses, such as human immunodeficiency virus (HIV). Thus, coupling of N-benzyloxycarbonyl-N-methyl-L-alanine with reduced peptide mimic I

(R1 = CMe3; R2 = H) (prepd. in 7 steps from N-benzyloxycarbonyl-L-phenylalanine chloromethyl ketone, isoamylamine, tert-Bu isocyanate, and N-benzyloxycarbonyl-L-tert-butylglycine), followed by catalytic deprotection, gave 54% desired inhibitor I (R1 = CMe3, R2 = Me-L-Ala) (II). II inhibited HIV-infected cells with IC50 = 8 nM, and EC50 = 96 mg/mL in the presence of AZT or DDI.

ST phenylstatine deriv prepn retroviral protease inhibitor; reduced phenylalanine peptide prepn HIV inhibitor

IT Anti-AIDS drugs  
Antiviral agents

Human immunodeficiency virus 1

(prepn. of phenylstatine derivs. as retroviral protease inhibitors)

IT 168056-64-2P 168056-65-3P 168056-66-4P 168056-68-6P 168056-69-7P  
168112-86-5P

RL: BAC (Biological activity or effector, except adverse); RCT

(Reactant);

SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of phenylstatine derivs. as retroviral protease inhibitors)

IT 143577-34-8P 155662-50-3P 159910-86-8P 168056-54-0P 168056-55-1P  
168056-56-2P 168056-57-3P 168056-58-4P 168056-59-5P 168056-60-8P  
168056-61-9P 168056-62-0P 168056-63-1P 168056-67-5P 168056-70-0P  
168112-84-3P 168112-85-4P 168112-87-6P 207614-10-6P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of phenylstatine derivs. as retroviral protease inhibitors)

IT 7481-89-2, DDC 23339-47-1, DAT 30516-87-1, AZT 69655-05-6, DDI  
**72599-27-0**, N-Butyl-1-deoxynojirimycin 79831-76-8,  
Castanospermine 106941-25-7, PMEAs **134678-17-4**, 3TC

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(prepn. of phenylstatine derivs. as retroviral protease inhibitors)

IT 127943-39-9P

RL: BYP (Byproduct); PREP (Preparation)

(prepn. of phenylstatine derivs. as retroviral protease inhibitors)

IT 63-91-2, L-Phenylalanine, reactions 107-85-7, Isoamylamine 541-88-8,  
Chloroacetic anhydride 1118-68-9, N,N-Dimethylaminoacetic acid  
1148-11-4 1609-86-5, tert-Butyl isocyanate 3182-95-4,

L-Phenylalaninol

3391-99-9 3392-08-3 4530-20-5 15761-39-4 21691-41-8,  
N-Benzyloxycarbonyl-N-methyl-L-alanine 26049-94-5 62965-10-0  
68223-03-0, N-Benzyloxycarbonyl-N-methyl-D-alanine 112898-22-3

RL: RCT (Reactant)

(prepn. of phenylstatine derivs. as retroviral protease inhibitors)

IT 111060-52-7P 111060-64-1P 111138-83-1P 127927-43-9P 128018-43-9P  
128018-44-0P 143224-67-3P 143224-89-9P 143224-90-2P 143224-91-3P  
143225-04-1P 168056-71-1P 168056-72-2P 168056-73-3P 168056-74-4P  
168056-75-5P 168056-76-6P 168056-77-7P 168056-78-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)

(prepn. of phenylstatine derivs. as retroviral protease inhibitors)

IT 37205-61-1, Protease inhibitor

RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL  
(Biological study)

(retroviral; prepn. of phenylstatine derivs. as retroviral protease  
inhibitors)

L7 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 1994:153741 CAPLUS

DN 120:153741

TI Use of antiretroviral drugs for treatment of motor neuron diseases

IN Westarp, Martin Egon; Kornhuber, Hans Helmut

PA Germany

SO Ger. Offen., 6 pp.

CODEN: GWXXBX

DT Patent

LA German

IC ICM A61K031-70

ICS A61K031-55; A61K031-505; A61K031-66; A61K031-445; A61K031-47

ICI A61K031-70, A61K031-55, A61K031-505, A61K031-66, A61K031-445, A61K031-47

CC 1-11 (Pharmacology)

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI DE 4307883	A1	19930923	DE 1993-4307883	19930312
---------------	----	----------	-----------------	----------

PRAI DE 1992-4207863		19920312		
----------------------	--	----------	--	--

AB Nucleoside analogs and other antiretroviral agents are useful for  
treatment of diseases of motor neurons, such as amyotrophic lateral  
sclerosis (ALS), spinal muscular atrophy, and progressive bulbar  
paralysis. Thus, administration of zidovudine (500 mg/day orally for

2-10

mo) to ALS patients reversed the elevation in serum creatine kinase level  
characteristic of ALS in 8 of 10 patients.

ST motor nerve disease treatment virucide; amyotrophic lateral sclerosis  
retrovirus drug; zidovudine nerve disease

IT Virucides and Virustats

(for retroviruses, motor neuron disease treatment with)

IT Ribonucleic acids, viral

RL: BIOL (Biological study)

(of retrovirus, antisense, motor neuron disease treatment with)

IT Virus, animal

(Maedi-Visna, antisense RNA of, motor neuron disease treatment with)

IT Paralysis

(bulbar, progressive, treatment of, with retrovirus inhibitors)

IT 63-91-2, L-Phenylalanine, reactions 107-85-7, Isoamylamine 541-88-8,  
Chloroacetic anhydride 1118-68-9, N,N-Dimethylaminoacetic acid  
1148-11-4 1609-86-5, tert-Butyl isocyanate 3182-95-4,

L-Phenylalaninol

3391-99-9 3392-08-3 4530-20-5 15761-39-4 21691-41-8,  
N-Benzylloxycarbonyl-N-methyl-L-alanine 26049-94-5 62965-10-0  
68223-03-0, N-Benzylloxycarbonyl-N-methyl-D-alanine 112898-22-3

RL: RCT (Reactant)

(prepn. of phenylstatine derivs. as retroviral protease inhibitors)

IT 111060-52-7P 111060-64-1P 111138-83-1P 127927-43-9P 128018-43-9P  
128018-44-0P 143224-67-3P 143224-89-9P 143224-90-2P 143224-91-3P  
143225-04-1P 168056-71-1P 168056-72-2P 168056-73-3P 168056-74-4P  
168056-75-5P 168056-76-6P 168056-77-7P 168056-78-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)

(prepn. of phenylstatine derivs. as retroviral protease inhibitors)

IT 37205-61-1, Protease inhibitor

RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL  
(Biological study)

(retroviral; prepn. of phenylstatine derivs. as retroviral protease  
inhibitors)

L7 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2001 ACS

AN 1994:153741 CAPLUS

DN 120:153741

TI Use of antiretroviral drugs for treatment of motor neuron diseases

IN Westarp, Martin Egon; Kornhuber, Hans Helmut

PA Germany

SO Ger. Offen., 6 pp.

CODEN: GWXXBX

DT Patent

LA German

IC ICM A61K031-70

ICS A61K031-55; A61K031-505; A61K031-66; A61K031-445; A61K031-47

ICI A61K031-70, A61K031-55, A61K031-505, A61K031-66, A61K031-445, A61K031-47

CC 1-11 (Pharmacology)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DE 4307883	A1	19930923	DE 1993-4307883	19930312
PRAI	DE 1992-4207863		19920312		
AB	Nucleoside analogs and other antiretroviral agents are useful for treatment of diseases of motor neurons, such as amyotrophic lateral sclerosis (ALS), spinal muscular atrophy, and progressive bulbar paralysis. Thus, administration of zidovudine (500 mg/day orally for				
2-10	mo) to ALS patients reversed the elevation in serum creatine kinase level characteristic of ALS in 8 of 10 patients.				
ST	motor nerve disease treatment virucide; amyotrophic lateral sclerosis retrovirus drug; zidovudine nerve disease				
IT	Virucides and Virustats				
	(for retroviruses, motor neuron disease treatment with)				
IT	Ribonucleic acids, viral				
	RL: BIOL (Biological study)				
	(of retrovirus, antisense, motor neuron disease treatment with)				
IT	Virus, animal				
	(Maedi-Visna, antisense RNA of, motor neuron disease treatment with)				
IT	Paralysis				
	(bulbar, progressive, treatment of, with retrovirus inhibitors)				

IT Nervous system  
 (disease, amyotrophic lateral sclerosis, treatment of, with retrovirus inhibitors)

IT Nervous system  
 (disease, spinal muscular atrophy, treatment of, with retrovirus inhibitors)

IT Virus, animal  
 (foamy, antisense RNA of, motor neuron disease treatment with)

IT Nerve, disease  
 (motor, treatment of, with retrovirus inhibitors)

IT Virus, animal  
 (retro-, inhibitors of, motor neuron disease treatment with)

IT Proteins, specific or class  
 RL: BIOL (Biological study)  
 (trichosanthins, motor neuron disease treatment with)

IT 9068-38-6, Reverse transcriptase  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitors, motor neuron disease treatment with)

IT 50-48-6, Amitriptyline 52-67-5 53-43-0, Dehydroepiandrosterone  
 62-46-4, 1,2-Dithiolane-3-pentanoic acid 70-00-8, Trifluorothymidine  
 360-97-4, 5-Aminoimidazole-4-carboxamide 548-04-9, Hypericin  
 616-91-1,  
 N-Acetylcysteine 1077-28-7 3056-17-5 4317-14-0, Amitriptyline oxide  
 4408-78-0, Phosphonoacetic acid 4428-95-9, Foscarnet 6493-05-6,  
 Pentoxifylline 6736-58-9, 3-Deazaadenosine 7481-89-2, Dideoxycytidine  
 9042-14-2, Dextran sulfate 16561-29-8 **19130-96-2**,  
 Deoxynojirimycin 19750-45-9 30195-30-3 30516-87-1, Azidothymidine  
 36791-04-5, Ribavirin 58821-98-0, 12-Deoxyphorbol 13-phenylacetate  
 59372-48-4, Ammonium antimony tungsten oxide 60857-08-1,  
 12-Deoxyphorbol  
 13-acetate 69655-05-6, Dideoxyinosine **72599-27-0**  
 112190-24-6, U-75875 123027-56-5 126347-69-1, R82913 127779-20-8  
 127875-60-9, A-80915A 129618-40-2, Nevirapine 132774-45-9  
 132774-46-0 134458-76-7 **134678-17-4** 134680-32-3  
 136816-67-6 136816-72-3, U 85961 136816-75-6, U 87201 136816-75-6D,  
 U 87201, esters 136816-76-7, U 88204 136816-84-7, U 88352  
 136816-85-8, U 88353 136891-12-8 137622-85-6 140459-12-7,  
 Fluorothymidine 143616-58-4 147362-54-7, R 18893 148465-15-0, L697  
 153374-32-4 153411-01-9 153550-37-9, L 661  
 RL: BIOL (Biological study)  
 (motor neuron disease treatment with)

=> d his

(FILE 'HOME' ENTERED AT 11:59:11 ON 27 SEP 2001)

FILE 'REGISTRY' ENTERED AT 11:59:22 ON 27 SEP 2001

E DEOXYNOJIRIMYCIN

L1 32 S E1-E3

L2 10 S 3TC

FILE 'CAPLUS' ENTERED AT 12:01:58 ON 27 SEP 2001

E HEPATITIS

L3 31704 S E3

L4 4491 S HBV

L5 751 S L1

L6 1070 S L2

IT Nervous system  
 (disease, amyotrophic lateral sclerosis, treatment of, with retrovirus inhibitors)

IT Nervous system  
 (disease, spinal muscular atrophy, treatment of, with retrovirus inhibitors)

IT Virus, animal  
 (foamy, antisense RNA of, motor neuron disease treatment with)

IT Nerve, disease  
 (motor, treatment of, with retrovirus inhibitors)

IT Virus, animal  
 (retro-, inhibitors of, motor neuron disease treatment with)

IT Proteins, specific or class  
 RL: BIOL (Biological study)  
 (trichosanthins, motor neuron disease treatment with)

IT 9068-38-6, Reverse transcriptase  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitors, motor neuron disease treatment with)

IT 50-48-6, Amitriptyline 52-67-5 53-43-0, Dehydroepiandrosterone  
 62-46-4, 1,2-Dithiolane-3-pentanoic acid 70-00-8, Trifluorothymidine  
 360-97-4, 5-Aminoimidazole-4-carboxamide 548-04-9, Hypericin  
 616-91-1,  
 N-Acetylcysteine 1077-28-7 3056-17-5 4317-14-0, Amitriptyline oxide  
 4408-78-0, Phosphonoacetic acid 4428-95-9, Foscarnet 6493-05-6,  
 Pentoxifylline 6736-58-9, 3-Deazaadenosine 7481-89-2, Dideoxycytidine  
 9042-14-2, Dextran sulfate 16561-29-8 **19130-96-2**,  
 Deoxynojirimycin 19750-45-9 30195-30-3 30516-87-1, Azidothymidine  
 36791-04-5, Ribavirin 58821-98-0, 12-Deoxyphorbol 13-phenylacetate  
 59372-48-4, Ammonium antimony tungsten oxide 60857-08-1,  
 12-Deoxyphorbol  
 13-acetate 69655-05-6, Dideoxyinosine **72599-27-0**  
 112190-24-6, U-75875 123027-56-5 126347-69-1, R82913 127779-20-8  
 127875-60-9, A-80915A 129618-40-2, Nevirapine 132774-45-9  
 132774-46-0 134458-76-7 **134678-17-4** 134680-32-3  
 136816-67-6 136816-72-3, U 85961 136816-75-6, U 87201 136816-75-6D,  
 U 87201, esters 136816-76-7, U 88204 136816-84-7, U 88352  
 136816-85-8, U 88353 136891-12-8 137622-85-6 140459-12-7,  
 Fluorothymidine 143616-58-4 147362-54-7, R 18893 148465-15-0, L697  
 153374-32-4 153411-01-9 153550-37-9, L 661  
 RL: BIOL (Biological study)  
 (motor neuron disease treatment with)

=> d his

(FILE 'HOME' ENTERED AT 11:59:11 ON 27 SEP 2001)

FILE 'REGISTRY' ENTERED AT 11:59:22 ON 27 SEP 2001

E DEOXYNOJIRIMYCIN

L1 32 S E1-E3

L2 10 S 3TC

FILE 'CAPLUS' ENTERED AT 12:01:58 ON 27 SEP 2001

E HEPATITIS

L3 31704 S E3

L4 4491 S HBV

L5 751 S L1

L6 1070 S L2



L7 16 S L5 AND L6

=> s 16 and 13

L8 271 L6 AND L3

=> s 18 and 14

L9 176 L8 AND L4

=> s 19 and antiviral

32353 ANTIVIRAL

L10 160 L9 AND ANTIVIRAL

=> d 110 110-160

L10 ANSWER 110 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1999:249268 CAPLUS

DN 131:82389

TI **Antiviral** treatment for human immunodeficiency virus patients co-infected with **hepatitis** B virus: combined effect for both infections, an obtainable goal?

AU Wolters, Leonieke M. M.; Niesters, Hubert G. M.; de Man, Robert A.; Schalm, Solko W.

CS Department of Hepatogastroenterology, University Hospital Rotterdam, Rotterdam, 3000 CA, Neth.

SO Antiviral Res. (1999), 42(1), 71-76

CODEN: ARSRDR; ISSN: 0166-3542

PB Elsevier Science B.V.

DT Journal; General Review

LA English

RE.CNT 19

RE

(3) Benhamou, Y; Ann Intern Med 1996, V125, P705 CAPLUS

(5) Boucher, C; Antimicrob Agents Chemother 1993, V37, P2231 CAPLUS

(8) Eron, J; New Engl J Med 1995, V333, P1662 CAPLUS

(11) Honkoop, P; J Hepatol 1997, V26, P1393 CAPLUS

(15) Ling, R; Hepatology 1996, V24, P711 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 111 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1999:209794 CAPLUS

DN 130:276292

TI Efficacy of lamivudine in patients with **hepatitis** B virus precore mutant infection before and after liver transplantation

AU Ben-Ari, Ziv; Zemel, Romy; Kazetsker, Anna; Fraser, Gerald; Tur-Kaspa, Ran

CS Liver Institute, Department of Medicine D, Tel Aviv University, Tel Aviv-Jaffa, Israel

SO Am. J. Gastroenterol. (1999), 94(3), 663-667

CODEN: AJGAAR; ISSN: 0002-9270

PB Elsevier Science Inc.

DT Journal

LA English

RE.CNT 21

RE

(2) Bain, V; Transplantation 1996, V62, P1456 CAPLUS

(4) Ben-Ari, Z; Transplantation 1997, V63, P393 CAPLUS

(7) Carman, W; Gastroenterology 1992, V102, P711 CAPLUS

(9) Dienstag, J; N Engl J Med 1995, V333, P1657 CAPLUS

L7 16 S L5 AND L6

=> s 16 and 13

L8 271 L6 AND L3

=> s 18 and 14

L9 176 L8 AND L4

=> s 19 and antiviral

32353 ANTIVIRAL

L10 160 L9 AND ANTIVIRAL

=> d 110 110-160

L10 ANSWER 110 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1999:249268 CAPLUS

DN 131:82389

TI **Antiviral** treatment for human immunodeficiency virus patients co-infected with **hepatitis** B virus: combined effect for both infections, an obtainable goal?

AU Wolters, Leonieke M. M.; Niesters, Hubert G. M.; de Man, Robert A.; Schalm, Solko W.

CS Department of Hepatogastroenterology, University Hospital Rotterdam, Rotterdam, 3000 CA, Neth.

SO Antiviral Res. (1999), 42(1), 71-76

CODEN: ARSRDR; ISSN: 0166-3542

PB Elsevier Science B.V.

DT Journal; General Review

LA English

RE.CNT 19

RE

(3) Benhamou, Y; Ann Intern Med 1996, V125, P705 CAPLUS

(5) Boucher, C; Antimicrob Agents Chemother 1993, V37, P2231 CAPLUS

(8) Eron, J; New Engl J Med 1995, V333, P1662 CAPLUS

(11) Honkoop, P; J Hepatol 1997, V26, P1393 CAPLUS

(15) Ling, R; Hepatology 1996, V24, P711 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 111 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1999:209794 CAPLUS

DN 130:276292

TI Efficacy of lamivudine in patients with **hepatitis** B virus precore mutant infection before and after liver transplantation

AU Ben-Ari, Ziv; Zemel, Romy; Kazetsker, Anna; Fraser, Gerald; Tur-Kaspa, Ran

CS Liver Institute, Department of Medicine D, Tel Aviv University, Tel Aviv-Jaffa, Israel

SO Am. J. Gastroenterol. (1999), 94(3), 663-667

CODEN: AJGAAR; ISSN: 0002-9270

PB Elsevier Science Inc.

DT Journal

LA English

RE.CNT 21

RE

(2) Bain, V; Transplantation 1996, V62, P1456 CAPLUS

(4) Ben-Ari, Z; Transplantation 1997, V63, P393 CAPLUS

(7) Carman, W; Gastroenterology 1992, V102, P711 CAPLUS

(9) Dienstag, J; N Engl J Med 1995, V333, P1657 CAPLUS

(15) Laskus, T; J Hepatol 1994, V20, P837 CAPLUS  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 112 OF 160 CAPLUS COPYRIGHT 2001 ACS  
AN 1999:198028 CAPLUS  
DN 131:39256  
TI YMDD motif in **hepatitis** B virus DNA polymerase influences on  
replication and lamivudine resistance: a study by in vitro full-length  
viral DNA transfection  
AU Ono-Nita, Suzane Kioko; Kato, Naoya; Shiratori, Yasushi; Masaki, Tsutomu;  
Lan, Keng-Hsin; Carrilho, Flair Jose; Omata, Masao  
CS Second Department of Internal Medicine, Faculty of Medicine, University  
of  
Tokyo, Tokyo, 113, Japan  
SO Hepatology (Philadelphia) (1999), 29(3), 939-945  
CODEN: HPTLD9; ISSN: 0270-9139  
PB W. B. Saunders Co.  
DT Journal  
LA English  
RE.CNT 43  
RE  
(2) Back, N; EMBO J 1996, V15, P4040 CAPLUS  
(3) Bain, V; Transplantation 1996, V62, P1456 CAPLUS  
(4) Balter, M; Science 1996, V274, P1988 CAPLUS  
(6) Ben-Ari, Z; Transplantation 1997, V63, P393 CAPLUS  
(7) Benhamou, Y; Ann Intern Med 1996, V125, P705 CAPLUS  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 113 OF 160 CAPLUS COPYRIGHT 2001 ACS  
AN 1999:198025 CAPLUS  
DN 131:39255  
TI Efficacy of lamivudine in patients with **hepatitis** B e  
antigen-negative/**hepatitis** B virus DNA-positive (precore mutant)  
chronic **hepatitis** B  
AU Tassopoulos, Nicolaos C.; Volpes, Riccardo; Pastore, Giuseppe; Heathcote,  
Jenny; Buti, Maria; Goldin, Robert D.; Hawley, Sasha; Barber, Judy;  
Condreay, Lynn; Gray, D. Fraser  
CS The Lamivudine Precore Mutant Study Group, Western Attica General  
Hospital, Athens, 123 51, Greece  
SO Hepatology (Philadelphia) (1999), 29(3), 889-896  
CODEN: HPTLD9; ISSN: 0270-9139  
PB W. B. Saunders Co.  
DT Journal  
LA English  
RE.CNT 41  
RE  
(2) Allen, M; Hepatology 1998, V27, P1670 CAPLUS  
(9) Dienstag, J; N Engl J Med 1995, V333, P1657 CAPLUS  
(10) Dusheiko, G; Pharmacol Ther 1995, V65, P47 CAPLUS  
(13) Fischer, K; Antimicrob Agents Chemother 1996, V40, P1957 CAPLUS  
(22) Lai, C; Hepatology 1997, V25, P241 CAPLUS  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 114 OF 160 CAPLUS COPYRIGHT 2001 ACS  
AN 1999:194745 CAPLUS  
DN 131:39251  
TI **Hepatitis** B virus variants with lamivudine-related mutations in  
the DNA polymerase and the 'a' epitope of the surface antigen are

(15) Laskus, T; J Hepatol 1994, V20, P837 CAPLUS  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 112 OF 160 CAPLUS COPYRIGHT 2001 ACS  
AN 1999:198028 CAPLUS  
DN 131:39256  
TI YMDD motif in **hepatitis** B virus DNA polymerase influences on  
replication and lamivudine resistance: a study by in vitro full-length  
viral DNA transfection  
AU Ono-Nita, Suzane Kioko; Kato, Naoya; Shiratori, Yasushi; Masaki, Tsutomu;  
Lan, Keng-Hsin; Carrilho, Flair Jose; Omata, Masao  
CS Second Department of Internal Medicine, Faculty of Medicine, University  
of  
Tokyo, Tokyo, 113, Japan  
SO Hepatology (Philadelphia) (1999), 29(3), 939-945  
CODEN: HPTLD9; ISSN: 0270-9139  
PB W. B. Saunders Co.  
DT Journal  
LA English  
RE.CNT 43  
RE  
(2) Back, N; EMBO J 1996, V15, P4040 CAPLUS  
(3) Bain, V; Transplantation 1996, V62, P1456 CAPLUS  
(4) Balter, M; Science 1996, V274, P1988 CAPLUS  
(6) Ben-Ari, Z; Transplantation 1997, V63, P393 CAPLUS  
(7) Benhamou, Y; Ann Intern Med 1996, V125, P705 CAPLUS  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 113 OF 160 CAPLUS COPYRIGHT 2001 ACS  
AN 1999:198025 CAPLUS  
DN 131:39255  
TI Efficacy of lamivudine in patients with **hepatitis** B e  
antigen-negative/**hepatitis** B virus DNA-positive (precore mutant)  
chronic **hepatitis** B  
AU Tassopoulos, Nicolaos C.; Volpes, Riccardo; Pastore, Giuseppe; Heathcote,  
Jenny; Buti, Maria; Goldin, Robert D.; Hawley, Sasha; Barber, Judy;  
Condreay, Lynn; Gray, D. Fraser  
CS The Lamivudine Precore Mutant Study Group, Western Attica General  
Hospital, Athens, 123 51, Greece  
SO Hepatology (Philadelphia) (1999), 29(3), 889-896  
CODEN: HPTLD9; ISSN: 0270-9139  
PB W. B. Saunders Co.  
DT Journal  
LA English  
RE.CNT 41  
RE  
(2) Allen, M; Hepatology 1998, V27, P1670 CAPLUS  
(9) Dienstag, J; N Engl J Med 1995, V333, P1657 CAPLUS  
(10) Dusheiko, G; Pharmacol Ther 1995, V65, P47 CAPLUS  
(13) Fischer, K; Antimicrob Agents Chemother 1996, V40, P1957 CAPLUS  
(22) Lai, C; Hepatology 1997, V25, P241 CAPLUS  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 114 OF 160 CAPLUS COPYRIGHT 2001 ACS  
AN 1999:194745 CAPLUS  
DN 131:39251  
TI **Hepatitis** B virus variants with lamivudine-related mutations in  
the DNA polymerase and the 'a' epitope of the surface antigen are

sensitive to ganciclovir  
 AU Jin Oon, Chong; Ning Chen, Wei; Lim, Nichole; Koh, Shiuan; Keow Lim, Gek;  
 Lin Leong, Ai; San Tan, Gek  
 CS Department of Clinical Research, Ransome Research Laboratory, Singapore  
 General Hospital, Singapore  
 SO Antiviral Res. (1999), 41(3), 113-118  
 CODEN: ARSRDR; ISSN: 0166-3542  
 PB Elsevier Science B.V.  
 DT Journal  
 LA English  
 RE.CNT 10  
 RE  
 (2) Carman, W; Hepatology 1997, V26, P1658 CAPLUS  
 (3) Carman, W; Lancet 1995, V345, P1406 CAPLUS  
 (4) Dienstag, J; N Engl J Med 1995, V333, P1657 CAPLUS  
 (5) Honkoop, P; J Hepatol 1997, V26, P1393 CAPLUS  
 (6) Lai, C; Hepatology 1997, V25, P241 CAPLUS  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 115 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1999:188556 CAPLUS  
 DN 131:238  
 TI Functional analysis of mutations conferring lamivudine resistance on  
**hepatitis B virus**  
 AU Ling, R.; Harrison, T. J.  
 CS Department of Medicine, Royal Free and University College Medical School,  
 University College London, London, NW3 2PF, UK  
 SO J. Gen. Virol. (1999), 80(3), 601-606  
 CODEN: JGVIAY; ISSN: 0022-1317  
 PB Society for General Microbiology  
 DT Journal  
 LA English  
 RE.CNT 30  
 RE  
 (1) Allen, M; Hepatology 1998, V27, P1670 CAPLUS  
 (2) Bain, V; Transplantation 1996, V62, P1456 CAPLUS  
 (4) Ben-Ari, Z; Transplantation 1997, V63, P393 CAPLUS  
 (6) Buti, M; Journal of Hepatology 1998, V28, P510 CAPLUS  
 (7) Chayama, K; Hepatology 1998, V27, P1711 CAPLUS  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 116 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1999:185603 CAPLUS  
 DN 130:291211  
 TI Good results of lamivudine in **hepatitis B** surface  
 antigen-positive patients with active viral replication before liver  
 transplantation  
 AU Gugenheim, J.; Baldini, E.; Ouzan, D.; Sowka, P.; Mouiel, J.  
 CS Service de Chirurgie Digestive, Universite de Sophia Antipolis, Nice, Fr.  
 SO Transplant. Proc. (1999), 31(1/2), 554-555  
 CODEN: TRPPA8; ISSN: 0041-1345  
 PB Elsevier Science Inc.  
 DT Journal  
 LA English  
 RE.CNT 8  
 RE  
 (1) Bain, V; Transplantation 1996, V62, P1456 CAPLUS  
 (2) Benhamou, Y; Lancet 1995, V345, P396 MEDLINE

sensitive to ganciclovir  
AU Jin Oon, Chong; Ning Chen, Wei; Lim, Nichole; Koh, Shiuan; Keow Lim, Gek;  
Lin Leong, Ai; San Tan, Gek  
CS Department of Clinical Research, Ransome Research Laboratory, Singapore  
General Hospital, Singapore  
SO Antiviral Res. (1999), 41(3), 113-118  
CODEN: ARSRDR; ISSN: 0166-3542  
PB Elsevier Science B.V.  
DT Journal  
LA English  
RE.CNT 10  
RE

- (2) Carman, W; Hepatology 1997, V26, P1658 CAPLUS
  - (3) Carman, W; Lancet 1995, V345, P1406 CAPLUS
  - (4) Dienstag, J; N Engl J Med 1995, V333, P1657 CAPLUS
  - (5) Honkoop, P; J Hepatol 1997, V26, P1393 CAPLUS
  - (6) Lai, C; Hepatology 1997, V25, P241 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 115 OF 160 CAPLUS COPYRIGHT 2001 ACS  
AN 1999:188556 CAPLUS  
DN 131:238  
TI Functional analysis of mutations conferring lamivudine resistance on  
**hepatitis** B virus  
AU Ling, R.; Harrison, T. J.  
CS Department of Medicine, Royal Free and University College Medical School,  
University College London, London, NW3 2PF, UK  
SO J. Gen. Virol. (1999), 80(3), 601-606  
CODEN: JGVIAY; ISSN: 0022-1317  
PB Society for General Microbiology  
DT Journal  
LA English  
RE.CNT 30  
RE

- (1) Allen, M; Hepatology 1998, V27, P1670 CAPLUS
  - (2) Bain, V; Transplantation 1996, V62, P1456 CAPLUS
  - (4) Ben-Ari, Z; Transplantation 1997, V63, P393 CAPLUS
  - (6) Buti, M; Journal of Hepatology 1998, V28, P510 CAPLUS
  - (7) Chayama, K; Hepatology 1998, V27, P1711 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 116 OF 160 CAPLUS COPYRIGHT 2001 ACS  
AN 1999:185603 CAPLUS  
DN 130:291211  
TI Good results of lamivudine in **hepatitis** B surface  
antigen-positive patients with active viral replication before liver  
transplantation  
AU Gugenheim, J.; Baldini, E.; Ouzan, D.; Sowka, P.; Mouiel, J.  
CS Service de Chirurgie Digestive, Universite de Sophia Antipolis, Nice, Fr.  
SO Transplant. Proc. (1999), 31(1/2), 554-555  
CODEN: TRPPA8; ISSN: 0041-1345  
PB Elsevier Science Inc.  
DT Journal  
LA English  
RE.CNT 8  
RE

- (1) Bain, V; Transplantation 1996, V62, P1456 CAPLUS
- (2) Benhamou, Y; Lancet 1995, V345, P396 MEDLINE

- (3) Dienstag, J; N Engl J Med 1995, V333, P1657 CAPLUS  
(5) Gugenheim, J; Trans Proc 1997, V29, P517 MEDLINE  
(6) Marcellin, P; Hepatology 1994, V19, P6 MEDLINE

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 117 OF 160 CAPLUS COPYRIGHT 2001 ACS  
AN 1999:167057 CAPLUS  
DN 130:252593  
TI The S-acyl-2-thioethyl pronucleotide approach applied to acyclovir. Part I. Synthesis and in vitro anti-**hepatitis** B virus activity of bis(S-acyl-2-thioethyl)phosphotriester derivatives of acyclovir  
AU Perigaud, Christian; Gosselin, Gilles; Girardet, Jean-Luc; Korba, Brent E.; Imbach, Jean-Louis  
CS U.M.R. C.N.R.S. 5625, Laboratoire de Chimie Bioorganique, Universite Montpellier II, Montpellier, 34095, Fr.  
SO Antiviral Res. (1999), 40(3), 167-178  
CODEN: ARSRDR; ISSN: 0166-3542  
PB Elsevier Science B.V.  
DT Journal  
LA English  
RE.CNT 40  
RE

- (2) Alexander, P; Collect Czech Chem Commun 1994, V59, P2127 CAPLUS  
(4) Aoki-Sei, S; J Infect Dis 1991, V164, P843 CAPLUS  
(5) Arner, E; Pharm Ther 1995, V67, P155 CAPLUS  
(6) Belen'Kii, M; Antiviral Res 1994, V25, P1 CAPLUS  
(8) Chou, T; Adv Enzyme Regul 1984, V22, P27 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 118 OF 160 CAPLUS COPYRIGHT 2001 ACS  
AN 1999:117751 CAPLUS  
DN 131:220  
TI The **hepatitis** B virus-trimera mouse: a model for human **HBV** infection and evaluation of anti-**HBV** therapeutic agents  
AU Ilan, Ehud; Burakova, Tatjana; Dagan, Shlomo; Nussbaum, Ofer; Lubin, Ido; Eren, Rachel; Ben-Moshe, Ofer; Arazi, Joseph; Berr, Shoshana; Neville, Lewis; Yuen, Leonard; Mansour, Tarek S.; Gillard, John; Eid, Ahamed; Jurim, Oded; Shouval, Daniel; Reisner, Yair; Galun, Eithan  
CS XTL Biopharmaceuticals Ltd, Rehovot, 76100, Israel  
SO Hepatology (Philadelphia) (1999), 29(2), 553-562  
CODEN: HPTLD9; ISSN: 0270-9139  
PB W. B. Saunders Co.  
DT Journal  
LA English  
RE.CNT 36  
RE

- (2) Cardillo, F; J Immunol Methods 1995, V188, P43 CAPLUS  
(3) Caselmann, W; Antiviral Res 1994, V24, P121 CAPLUS  
(4) Chisari, F; Cell 1989, V59, P1145 CAPLUS  
(5) Chisari, F; J Virol 1986, V60, P880 CAPLUS  
(6) Chomczynski, P; Biotechniques 1997, V22, P550 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 119 OF 160 CAPLUS COPYRIGHT 2001 ACS  
AN 1999:109354 CAPLUS  
DN 130:246369  
TI Lamivudine therapy for chemotherapy-induced reactivation of

- (3) Dienstag, J; N Engl J Med 1995, V333, P1657 CAPLUS  
(5) Gugenheim, J; Trans Proc 1997, V29, P517 MEDLINE  
(6) Marcellin, P; Hepatology 1994, V19, P6 MEDLINE  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 117 OF 160 CAPLUS COPYRIGHT 2001 ACS  
AN 1999:167057 CAPLUS  
DN 130:252593  
TI The S-acyl-2-thioethyl pronucleotide approach applied to acyclovir. Part I. Synthesis and in vitro anti-**hepatitis** B virus activity of bis(S-acyl-2-thioethyl)phosphotriester derivatives of acyclovir  
AU Perigaud, Christian; Gosselin, Gilles; Girardet, Jean-Luc; Korba, Brent E.; Imbach, Jean-Louis  
CS U.M.R. C.N.R.S. 5625, Laboratoire de Chimie Bioorganique, Universite Montpellier II, Montpellier, 34095, Fr.  
SO Antiviral Res. (1999), 40(3), 167-178  
CODEN: ARSRDR; ISSN: 0166-3542  
PB Elsevier Science B.V.  
DT Journal  
LA English  
RE.CNT 40  
RE  
(2) Alexander, P; Collect Czech Chem Commun 1994, V59, P2127 CAPLUS  
(4) Aoki-Sei, S; J Infect Dis 1991, V164, P843 CAPLUS  
(5) Arner, E; Pharm Ther 1995, V67, P155 CAPLUS  
(6) Belen'Kii, M; Antiviral Res 1994, V25, P1 CAPLUS  
(8) Chou, T; Adv Enzyme Regul 1984, V22, P27 CAPLUS  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 118 OF 160 CAPLUS COPYRIGHT 2001 ACS  
AN 1999:117751 CAPLUS  
DN 131:220  
TI The **hepatitis** B virus-trimera mouse: a model for human **HBV** infection and evaluation of anti-**HBV** therapeutic agents  
AU Ilan, Ehud; Burakova, Tatjana; Dagan, Shlomo; Nussbaum, Ofer; Lubin, Ido; Eren, Rachel; Ben-Moshe, Ofer; Arazi, Joseph; Berr, Shoshana; Neville, Lewis; Yuen, Leonard; Mansour, Tarek S.; Gillard, John; Eid, Ahamed; Jurim, Oded; Shouval, Daniel; Reisner, Yair; Galun, Eithan  
CS XTL Biopharmaceuticals Ltd, Rehovot, 76100, Israel  
SO Hepatology (Philadelphia) (1999), 29(2), 553-562  
CODEN: HPTLD9; ISSN: 0270-9139  
PB W. B. Saunders Co.  
DT Journal  
LA English  
RE.CNT 36  
RE  
(2) Cardillo, F; J Immunol Methods 1995, V188, P43 CAPLUS  
(3) Caselmann, W; Antiviral Res 1994, V24, P121 CAPLUS  
(4) Chisari, F; Cell 1989, V59, P1145 CAPLUS  
(5) Chisari, F; J Virol 1986, V60, P880 CAPLUS  
(6) Chomczynski, P; Biotechniques 1997, V22, P550 CAPLUS  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 119 OF 160 CAPLUS COPYRIGHT 2001 ACS  
AN 1999:109354 CAPLUS  
DN 130:246369  
TI Lamivudine therapy for chemotherapy-induced reactivation of



**hepatitis B virus infection**

AU Ahmed, Aijaz; Keefte, Emmet B.  
CS Division of Gastroenterology, Department of Medicine, Stanford University  
School of Medicine, Stanford, CA, USA  
SO Am. J. Gastroenterol. (1999), 94(1), 249-251  
CODEN: AJGAAR; ISSN: 0002-9270  
PB Elsevier Science Inc.  
DT Journal  
LA English  
RE.CNT 40  
RE

- (3) Benhamou, Y; Lancet 1995, V345, P396 MEDLINE
- (4) Bird, G; Q J Med 1989, V73, P895 MEDLINE
- (5) Dienstag, J; N Eng J Med 1995, V333, P1657 CAPLUS
- (6) Flowers, M; Ann Intern Med 1990, V112, P381 MEDLINE
- (32) Rostaing, L; Transplantation 1997, V64, P1624 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 120 OF 160 CAPLUS COPYRIGHT 2001 ACS  
AN 1999:37155 CAPLUS  
DN 130:276259

TI Transient selection of a **hepatitis B** virus polymerase gene  
mutant associated with a decreased replication capacity and famciclovir  
resistance  
AU Pichoud, Christian; Seignerres, Beatrice; Wang, Zhirui; Trepo, Christian;  
Zoulim, Fabien  
CS INSERM Unit 271, Lyon, 69003, Fr.  
SO Hepatology (Philadelphia) (1999), 29(1), 230-237  
CODEN: HPTLD9; ISSN: 0270-9139  
PB W. B. Saunders Co.  
DT Journal  
LA English  
RE.CNT 40  
RE

- (1) Arts, E; Antimicrob Agents Chemother 1996, V40, P527 CAPLUS
  - (6) Dannaoui, E; Antivir Chem Chemother 1997, V8, P38 CAPLUS
  - (7) Dienstag, J; N Engl J Med 1995, V333, P1657 CAPLUS
  - (9) Honkoop, P; J Hepatol 1997, V26, P1393 CAPLUS
  - (11) Horwich, A; J Virol 1990, V64, P642 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 121 OF 160 CAPLUS COPYRIGHT 2001 ACS  
AN 1999:12153 CAPLUS  
DN 130:204703

TI Lamivudine treatment for acute **hepatitis B** after liver  
transplantation  
AU Andreone, Pietro; Caraceni, Paolo; Grazi, Gian Luca; Belli, Luca;  
Milandri, Gian Luigi; Ercolani, Giorgio; Jovine, Elio; D'Errico, Antonia;  
Monte, Pier Roberto Dal; Ideo, Gaetano; Forti, Domenico; Mazziotti,  
Alighieri; Cavallari, Antonino; Bernardi, Mauro  
CS Dipartimento di Medicina Interna, Cardioangiologia ed Epatologia,  
University of Bologna, Bologna, Italy  
SO J. Hepatol. (1998), 29(6), 985-989  
CODEN: JOHEEC; ISSN: 0168-8278  
PB Munksgaard International Publishers Ltd.  
DT Journal  
LA English  
RE.CNT 12

**hepatitis B virus infection**  
 AU Ahmed, Aijaz; Keefe, Emmet B.  
 CS Division of Gastroenterology, Department of Medicine, Stanford University  
 School of Medicine, Stanford, CA, USA  
 SO Am. J. Gastroenterol. (1999), 94(1), 249-251  
 CODEN: AJGAAR; ISSN: 0002-9270  
 PB Elsevier Science Inc.  
 DT Journal  
 LA English  
 RE.CNT 40  
 RE  
 (3) Benhamou, Y; Lancet 1995, V345, P396 MEDLINE  
 (4) Bird, G; Q J Med 1989, V73, P895 MEDLINE  
 (5) Dienstag, J; N Eng J Med 1995, V333, P1657 CAPLUS  
 (6) Flowers, M; Ann Intern Med 1990, V112, P381 MEDLINE  
 (32) Rostaing, L; Transplantation 1997, V64, P1624 CAPLUS  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 120 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1999:37155 CAPLUS  
 DN 130:276259  
 TI Transient selection of a **hepatitis B** virus polymerase gene  
 mutant associated with a decreased replication capacity and famciclovir  
 resistance  
 AU Pichoud, Christian; Seigneres, Beatrice; Wang, Zhirui; Trepo, Christian;  
 Zoulim, Fabien  
 CS INSERM Unit 271, Lyon, 69003, Fr.  
 SO Hepatology (Philadelphia) (1999), 29(1), 230-237  
 CODEN: HPTLD9; ISSN: 0270-9139  
 PB W. B. Saunders Co.  
 DT Journal  
 LA English  
 RE.CNT 40  
 RE  
 (1) Arts, E; Antimicrob Agents Chemother 1996, V40, P527 CAPLUS  
 (6) Dannaoui, E; Antivir Chem Chemother 1997, V8, P38 CAPLUS  
 (7) Dienstag, J; N Engl J Med 1995, V333, P1657 CAPLUS  
 (9) Honkoop, P; J Hepatol 1997, V26, P1393 CAPLUS  
 (11) Horwich, A; J Virol 1990, V64, P642 CAPLUS  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 121 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1999:12153 CAPLUS  
 DN 130:204703  
 TI Lamivudine treatment for acute **hepatitis B** after liver  
 transplantation  
 AU Andreone, Pietro; Caraceni, Paolo; Grazi, Gian Luca; Belli, Luca;  
 Milandri, Gian Luigi; Ercolani, Giorgio; Jovine, Elio; D'Errico, Antonia;  
 Monte, Pier Roberto Dal; Ideo, Gaetano; Forti, Domenico; Mazziotti,  
 Alighieri; Cavallari, Antonino; Bernardi, Mauro  
 CS Dipartimento di Medicina Interna, Cardioangiologia ed Epatologia,  
 University of Bologna, Bologna, Italy  
 SO J. Hepatol. (1998), 29(6), 985-989  
 CODEN: JOHEEC; ISSN: 0168-8278  
 PB Munksgaard International Publishers Ltd.  
 DT Journal  
 LA English  
 RE.CNT 12

RE

- (1) Al Faraidy, K; Transplantation 1997, V64, P926 MEDLINE
- (3) Bain, V; Transplantation 1996, V62, P1456 CAPLUS
- (4) Ben-Ari, Z; Transplantation 1997, V63, P393 CAPLUS
- (7) Nevens, F; Gastroenterology 1997, V113, P1258 CAPLUS
- (12) Tipples, G; Hepatology 1996, V24, P714 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 122 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1998:810358 CAPLUS

DN 130:217639

TI Mutations in **hepatitis** B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

AU Xiong, Xiaofeng; Flores, Carmina; Yang, Huiling; Toole, John J.; Gibbs, Graig S.

CS Gilead Sciences, Foster City, CA, 94404, USA

SO Hepatology (Philadelphia) (1998), 28(6), 1669-1673

CODEN: HPTLD9; ISSN: 0270-9139

PB W. B. Saunders Co.

DT Journal

LA English

RE.CNT 39

RE

- (6) Cleland, W; Methods in Enzymology 1979, V63, P103 CAPLUS
- (7) de Clercq, E; Antiviral Res 1987, V8, P261 CAPLUS
- (8) de Clercq, E; Nature 1986, V323, P464 CAPLUS
- (9) de Clercq, E; Nucleosides Nucleotides 1994, V13, P1271 CAPLUS
- (10) Dienstag, J; N Engl J Med 1995, V333, P1657 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 123 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1998:719749 CAPLUS

DN 130:75800

TI Pharmacodynamics of (-)-.beta.-2',3'-dideoxy-3'-thiacytidine in chronically virus-infected woodchucks compared to its pharmacodynamics in humans

AU Hurwitz, Selwyn J.; Tennant, Bud C.; Korba, Brent E.; Gerin, John L.; Schinazi, Raymond F.

CS Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Veterans Affairs Medical Center, Decatur, GA, 300337, USA

SO Antimicrob. Agents Chemother. (1998), 42(11), 2804-2809

CODEN: AMACCQ; ISSN: 0066-4804

PB American Society for Microbiology

DT Journal

LA English

RE.CNT 27

RE

- (3) Cammack, N; Biochem Pharmacol 1992, V43, P2059 CAPLUS
- (4) Chang, C; J Biol Chem 1992, V267, P13938 CAPLUS
- (5) Fourel, I; J Virol 1994, V68, P8321 CAPLUS
- (11) Korba, B; Hepatology 1996, V23, P958 CAPLUS
- (15) Moore, K; Clin Pharmacol Ther 1996, V59, P550 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 124 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1998:681693 CAPLUS

DN 130:75790

RE

- (1) Al Faraidy, K; Transplantation 1997, V64, P926 MEDLINE
- (3) Bain, V; Transplantation 1996, V62, P1456 CAPLUS
- (4) Ben-Ari, Z; Transplantation 1997, V63, P393 CAPLUS
- (7) Nevens, F; Gastroenterology 1997, V113, P1258 CAPLUS
- (12) Tipples, G; Hepatology 1996, V24, P714 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 122 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1998:810358 CAPLUS

DN 130:217639

TI Mutations in **hepatitis** B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

AU Xiong, Xiaofeng; Flores, Carmina; Yang, Huiling; Toole, John J.; Gibbs, Graig S.

CS Gilead Sciences, Foster City, CA, 94404, USA

SO Hepatology (Philadelphia) (1998), 28(6), 1669-1673

CODEN: HPTLD9; ISSN: 0270-9139

PB W. B. Saunders Co.

DT Journal

LA English

RE.CNT 39

RE

- (6) Cleland, W; Methods in Enzymology 1979, V63, P103 CAPLUS
- (7) de Clercq, E; Antiviral Res 1987, V8, P261 CAPLUS
- (8) de Clercq, E; Nature 1986, V323, P464 CAPLUS
- (9) de Clercq, E; Nucleosides Nucleotides 1994, V13, P1271 CAPLUS
- (10) Dienstag, J; N Engl J Med 1995, V333, P1657 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 123 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1998:719749 CAPLUS

DN 130:75800

TI Pharmacodynamics of (-)-.beta.-2',3'-dideoxy-3'-thiacytidine in chronically virus-infected woodchucks compared to its pharmacodynamics in humans

AU Hurwitz, Selwyn J.; Tennant, Bud C.; Korba, Brent E.; Gerin, John L.; Schinazi, Raymond F.

CS Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Veterans Affairs Medical Center, Decatur, GA, 300337, USA

SO Antimicrob. Agents Chemother. (1998), 42(11), 2804-2809

CODEN: AMACCQ; ISSN: 0066-4804

PB American Society for Microbiology

DT Journal

LA English

RE.CNT 27

RE

- (3) Cammack, N; Biochem Pharmacol 1992, V43, P2059 CAPLUS
- (4) Chang, C; J Biol Chem 1992, V267, P13938 CAPLUS
- (5) Fourel, I; J Virol 1994, V68, P8321 CAPLUS
- (11) Korba, B; Hepatology 1996, V23, P958 CAPLUS
- (15) Moore, K; Clin Pharmacol Ther 1996, V59, P550 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 124 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1998:681693 CAPLUS

DN 130:75790

TI Transient emergence of **hepatitis** B variants in a patient with  
chronic **hepatitis** B resistant to lamivudine  
AU Buti, Maria; Jardi, Rosendo; Cotrina, Montserrat; Rodriguez-Frias,  
Francisco; Esteban, Rafael; Guardia, Jaime  
CS Liver Unit, Hospital General Universitario Valle Hebron, Barcelona,  
08035,  
Spain  
SO J. Hepatol. (1998), 28(3), 510-513  
CODEN: JOHEEC; ISSN: 0168-8278  
PB Munksgaard International Publishers Ltd.  
DT Journal  
LA English  
RE.CNT 11  
RE

(1) Bartholomew, M; Lancet 1997, V349, P20 MEDLINE  
(4) Grellier, L; Lancet 1996, V348, P1212 MEDLINE  
(6) Lai, C; Hepatology 1997, V25, P241 CAPLUS  
(7) Ling, R; Hepatology 1996, V24, P711 CAPLUS  
(11) Tipples, G; Hepatology 1996, V24, P714 CAPLUS  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 125 OF 160 CAPLUS COPYRIGHT 2001 ACS  
AN 1998:681420 CAPLUS  
DN 130:75788  
TI Clinical impact of lamivudine resistance in chronic **hepatitis** B  
AU Honkoop, Pieter; De Man, Robert A.; Niesters, Hubert G. M.; Schalm, Solko  
W.  
CS Department of Hepatogastroenterology, Erasmus University Hospital,  
Rotterdam, Neth.  
SO J. Hepatol. (1998), 29(3), 510-511  
CODEN: JOHEEC; ISSN: 0168-8278  
PB Munksgaard International Publishers Ltd.  
DT Journal  
LA English  
RE.CNT 5  
RE

(1) Bartholomew, M; Lancet 1997, V349, P20 MEDLINE  
(2) de Man, R; To be published in J Hepatol 1998  
(3) Honkoop, P; J Hepatol 1997, V26, P1393 CAPLUS  
(4) Leung, N; Hepatology 1997, V26(Suppl), P357  
(5) Niesters, H; J Infect Dis 1998, V177, P1382 CAPLUS

L10 ANSWER 126 OF 160 CAPLUS COPYRIGHT 2001 ACS  
AN 1998:680662 CAPLUS  
DN 130:75781  
TI Combination alpha-interferon and lamivudine therapy for  
alpha-interferon-resistant chronic **hepatitis** B infection:  
results of a pilot study  
AU Mutimer, David; Naoumov, Nicolai; Honkoop, Pieter; Marinos, George;  
Ahmed,  
Monz; de Man, Robert; McPhillips, Penny; Johnson, Mark; Williams, Roger;  
Elias, Elwyn; Schalm, Solko  
CS Liver and Hepatobiliary Unit, Queen Elizabeth Hospital, Birmingham, B15  
2TH, UK  
SO J. Hepatol. (1998), 28(6), 923-929  
CODEN: JOHEEC; ISSN: 0168-8278  
PB Munksgaard International Publishers Ltd.  
DT Journal

TI Transient emergence of **hepatitis** B variants in a patient with  
chronic **hepatitis** B resistant to lamivudine  
AU Buti, Maria; Jardi, Rosendo; Cotrina, Montserrat; Rodriguez-Frias,  
Francisco; Esteban, Rafael; Guardia, Jaime  
CS Liver Unit, Hospital General Universitario Valle Hebron, Barcelona,  
08035,  
Spain  
SO J. Hepatol. (1998), 28(3), 510-513  
CODEN: JOHEEC; ISSN: 0168-8278  
PB Munksgaard International Publishers Ltd.  
DT Journal  
LA English  
RE.CNT 11  
RE

(1) Bartholomew, M; Lancet 1997, V349, P20 MEDLINE  
(4) Grellier, L; Lancet 1996, V348, P1212 MEDLINE  
(6) Lai, C; Hepatology 1997, V25, P241 CAPLUS  
(7) Ling, R; Hepatology 1996, V24, P711 CAPLUS  
(11) Tipples, G; Hepatology 1996, V24, P714 CAPLUS  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 125 OF 160 CAPLUS COPYRIGHT 2001 ACS  
AN 1998:681420 CAPLUS  
DN 130:75788  
TI Clinical impact of lamivudine resistance in chronic **hepatitis** B  
AU Honkoop, Pieter; De Man, Robert A.; Niesters, Hubert G. M.; Schalm, Solko  
W.  
CS Department of Hepatogastroenterology, Erasmus University Hospital,  
Rotterdam, Neth.  
SO J. Hepatol. (1998), 29(3), 510-511  
CODEN: JOHEEC; ISSN: 0168-8278  
PB Munksgaard International Publishers Ltd.  
DT Journal  
LA English  
RE.CNT 5  
RE  
(1) Bartholomew, M; Lancet 1997, V349, P20 MEDLINE  
(2) de Man, R; To be published in J Hepatol 1998  
(3) Honkoop, P; J Hepatol 1997, V26, P1393 CAPLUS  
(4) Leung, N; Hepatology 1997, V26(Suppl), P357  
(5) Niesters, H; J Infect Dis 1998, V177, P1382 CAPLUS

L10 ANSWER 126 OF 160 CAPLUS COPYRIGHT 2001 ACS  
AN 1998:680662 CAPLUS  
DN 130:75781  
TI Combination alpha-interferon and lamivudine therapy for  
alpha-interferon-resistant chronic **hepatitis** B infection:  
results of a pilot study  
AU Mutimer, David; Naoumov, Nicolai; Honkoop, Pieter; Marinos, George;  
Ahmed,  
Monz; de Man, Robert; McPhillips, Penny; Johnson, Mark; Williams, Roger;  
Elias, Elwyn; Schalm, Solko  
CS Liver and Hepatobiliary Unit, Queen Elizabeth Hospital, Birmingham, B15  
2TH, UK  
SO J. Hepatol. (1998), 28(6), 923-929  
CODEN: JOHEEC; ISSN: 0168-8278  
PB Munksgaard International Publishers Ltd.  
DT Journal

LA English

RE.CNT 23

RE

- (4) Cui, L; J Clin Invest 1995, V95, P555 CAPLUS
- (6) Dienstag, J; N Engl J Med 1995, V333, P1657 CAPLUS
- (7) Eron, J; N Engl J Med 1995, V333, P1662 CAPLUS
- (10) Harker, A; J Chromatogr 1994, V657, P227 CAPLUS
- (12) Honkoop, P; Hepatology 1997, V26, P211 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 127 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1998:623468 CAPLUS

DN 130:20231

TI Robustaflavone, a potential non-nucleoside anti-**hepatitis B** agent

AU Zembower, David E.; Lin, Yuh-Meei; Flavin, Michael T.; Fa-Ching Chen; Korba, Brent E.

CS MediChem Research, Inc., Lemont, IL, 60439, USA

SO Antiviral Res. (1998), 39(2), 81-88

CODEN: ARSRDR; ISSN: 0166-3542

PB Elsevier Science B.V.

DT Journal

LA English

RE.CNT 27

RE

- (4) Belen'kii, M; Antiviral Res 1994, V25, P1 CAPLUS
- (5) Benhamou, Y; Ann Intern Med 1996, V125, P705 CAPLUS
- (7) Chen, F; Phytochemistry 1974, V13, P276 CAPLUS
- (8) Chen, F; Phytochemistry 1975, V14, P1644 CAPLUS
- (9) Chen, F; Phytochemistry 1975, V14, P300 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 128 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1998:584963 CAPLUS

DN 129:298066

TI Lamivudine treatment can restore T cell responsiveness in chronic **hepatitis B**

AU Boni, Carolina; Bertoletti, Antonio; Penna, Amalia; Cavalli, Albertina; Pilli, Massimo; Urbani, Simona; Scognamiglio, Paola; Boehme, Richard; Panebianco, Ruggero; Fiaccadori, Franco; Ferrari, Carlo

CS Laboratorio di Immunopatologia Virale, Divisione Malattie Infettive, Universita di Parma, Azienda Ospedaliera di Parma, Parma, Italy

SO J. Clin. Invest. (1998), 102(5), 968-975

CODEN: JCINAO; ISSN: 0021-9738

PB Rockefeller University Press

DT Journal

LA English

L10 ANSWER 129 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1998:582473 CAPLUS

DN 129:339487

TI Lamivudine inhibits **hepatitis B** virus replication in kidney graft recipients

AU Goffin, Eric; Horsmans, Yves; Cornu, Chantal; Squifflet, Jean-Paul; Pirson, Yves

CS Departments of Nephrology, Hepatology, Virology, and Renal Transplantation, Louvain Medical School, Hopital Saint-Luc, Brussels, 1200, Belg.

LA English

RE.CNT 23

RE

- (4) Cui, L; J Clin Invest 1995, V95, P555 CAPLUS
- (6) Dienstag, J; N Engl J Med 1995, V333, P1657 CAPLUS
- (7) Eron, J; N Engl J Med 1995, V333, P1662 CAPLUS
- (10) Harker, A; J Chromatogr 1994, V657, P227 CAPLUS
- (12) Honkoop, P; Hepatology 1997, V26, P211 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 127 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1998:623468 CAPLUS

DN 130:20231

TI Robustaflavone, a potential non-nucleoside anti-**hepatitis B**  
agent

AU Zembower, David E.; Lin, Yuh-Meei; Flavin, Michael T.; Fa-Ching Chen;  
Korba, Brent E.

CS MediChem Research, Inc., Lemont, IL, 60439, USA

SO Antiviral Res. (1998), 39(2), 81-88

CODEN: ARSRDR; ISSN: 0166-3542

PB Elsevier Science B.V.

DT Journal

LA English

RE.CNT 27

RE

- (4) Belen'kii, M; Antiviral Res 1994, V25, P1 CAPLUS
- (5) Benhamou, Y; Ann Intern Med 1996, V125, P705 CAPLUS
- (7) Chen, F; Phytochemistry 1974, V13, P276 CAPLUS
- (8) Chen, F; Phytochemistry 1975, V14, P1644 CAPLUS
- (9) Chen, F; Phytochemistry 1975, V14, P300 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 128 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1998:584963 CAPLUS

DN 129:298066

TI Lamivudine treatment can restore T cell responsiveness in chronic  
**hepatitis B**

AU Boni, Carolina; Bertoletti, Antonio; Penna, Amalia; Cavalli, Albertina;  
Pilli, Massimo; Urbani, Simona; Scognamiglio, Paola; Boehme, Richard;  
Panebianco, Ruggero; Fiaccadori, Franco; Ferrari, Carlo

CS Laboratorio di Immunopatologia Virale, Divisione Malattie Infettive,  
Universita di Parma, Azienda Ospedaliera di Parma, Parma, Italy

SO J. Clin. Invest. (1998), 102(5), 968-975

CODEN: JCINAO; ISSN: 0021-9738

PB Rockefeller University Press

DT Journal

LA English

L10 ANSWER 129 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1998:582473 CAPLUS

DN 129:339487

TI Lamivudine inhibits **hepatitis B** virus replication in kidney  
graft recipients

AU Goffin, Eric; Horsmans, Yves; Cornu, Chantal; Squifflet, Jean-Paul;  
Pirson, Yves

CS Departments of Nephrology, Hepatology, Virology, and Renal  
Transplantation, Louvain Medical School, Hopital Saint-Luc, Brussels,  
1200, Belg.



SO Transplantation (1998), 66(3), 407-409  
CODEN: TRPLAU; ISSN: 0041-1337  
PB Williams & Wilkins  
DT Journal  
LA English

L10 ANSWER 130 OF 160 CAPLUS COPYRIGHT 2001 ACS  
AN 1998:555499 CAPLUS  
DN 129:285629  
TI Prophylaxis against **hepatitis** B recurrence following liver  
transplantation using combination lamivudine and **hepatitis** B  
immune globulin  
AU Markovitz, Jay S.; Martin, Paul; Conrad, Andrew J.; Markmann, James; Seu,  
Philip; Yersiz, Hasan; Goss, John; Schmidt, Peter; Pakrasi, Anita;  
Artinian, Lucy; Murray, Natalie G. B.; Imagawa, David K.; Holt, Curtis;  
Goldstein, Leonard I.; Stribling, Rise; Busuttil, Ronald W.  
CS The Dumont-UCLA Transplant Center, Division of Liver and Pancreas  
Transplantation, UCLA Medical Center, Los Angeles, CA, USA  
SO Hepatology (Philadelphia) (1998), 28(2), 585-589  
CODEN: HPTLDD; ISSN: 0270-9139  
PB W. B. Saunders Co.  
DT Journal  
LA English

L10 ANSWER 131 OF 160 CAPLUS COPYRIGHT 2001 ACS  
AN 1998:514668 CAPLUS  
DN 129:254232  
TI Experience with lamivudine against **hepatitis** B virus  
AU Jaeckel, Elmar; Manns, Michael P.  
CS Department of Gastroenterology and Hepatology, Medizinische Hochschule  
Hannover, Hannover, D-30625, Germany  
SO Intervirology (1998), Volume Date 1997, 40(5-6), 322-336  
CODEN: IVRYAK; ISSN: 0300-5526  
PB S. Karger AG  
DT Journal; General Review  
LA English

L10 ANSWER 132 OF 160 CAPLUS COPYRIGHT 2001 ACS  
AN 1998:480978 CAPLUS  
DN 129:254380  
TI A one-year trial of lamivudine for chronic **hepatitis** B  
AU Lai, Ching-Lung; Chien, Rong-Nan; Leung, Nancy W. Y.; Chang, Ting-Tsung;  
Guan, Richard; Tai, Dar-In; Ng, Keng-Yeen; Wu, Pui-Chee; Dent, Julie C.;  
Barber, Judy; Stephenson, Sally L.; Gray, D. Fraser  
CS Department of Medicine, Queen Mary Hospital, Hong Kong, Peop. Rep. China  
SO N. Engl. J. Med. (1998), 339(2), 61-68  
CODEN: NEJMAG; ISSN: 0028-4793  
PB Massachusetts Medical Society  
DT Journal  
LA English

L10 ANSWER 133 OF 160 CAPLUS COPYRIGHT 2001 ACS  
AN 1998:471054 CAPLUS  
DN 129:225320  
TI Efficacy of lamivudine in controlling **hepatitis** B virus  
recurrence after liver transplantation  
AU Nery, Jose R.; Weppler, Deborah; Rodriguez, Miguel; Ruiz, Phillip;  
Schiff,

SO Transplantation (1998), 66(3), 407-409  
CODEN: TRPLAU; ISSN: 0041-1337  
PB Williams & Wilkins  
DT Journal  
LA English

L10 ANSWER 130 OF 160 CAPLUS COPYRIGHT 2001 ACS  
AN 1998:555499 CAPLUS  
DN 129:285629  
TI Prophylaxis against **hepatitis** B recurrence following liver  
transplantation using combination lamivudine and **hepatitis** B  
immune globulin  
AU Markovitz, Jay S.; Martin, Paul; Conrad, Andrew J.; Markmann, James; Seu,  
Philip; Yersiz, Hasan; Goss, John; Schmidt, Peter; Pakrasi, Anita;  
Artinian, Lucy; Murray, Natalie G. B.; Imagawa, David K.; Holt, Curtis;  
Goldstein, Leonard I.; Stribling, Rise; Busuttil, Ronald W.  
CS The Dumont-UCLA Transplant Center, Division of Liver and Pancreas  
Transplantation, UCLA Medical Center, Los Angeles, CA, USA  
SO Hepatology (Philadelphia) (1998), 28(2), 585-589  
CODEN: HPTLDD; ISSN: 0270-9139  
PB W. B. Saunders Co.  
DT Journal  
LA English

L10 ANSWER 131 OF 160 CAPLUS COPYRIGHT 2001 ACS  
AN 1998:514668 CAPLUS  
DN 129:254232  
TI Experience with lamivudine against **hepatitis** B virus  
AU Jaeckel, Elmar; Manns, Michael P.  
CS Department of Gastroenterology and Hepatology, Medizinische Hochschule  
Hannover, Hannover, D-30625, Germany  
SO Intervirology (1998), Volume Date 1997, 40(5-6), 322-336  
CODEN: IVRYAK; ISSN: 0300-5526  
PB S. Karger AG  
DT Journal; General Review  
LA English

L10 ANSWER 132 OF 160 CAPLUS COPYRIGHT 2001 ACS  
AN 1998:480978 CAPLUS  
DN 129:254380  
TI A one-year trial of lamivudine for chronic **hepatitis** B  
AU Lai, Ching-Lung; Chien, Rong-Nan; Leung, Nancy W. Y.; Chang, Ting-Tsung;  
Guan, Richard; Tai, Dar-In; Ng, Keng-Yeen; Wu, Pui-Chee; Dent, Julie C.;  
Barber, Judy; Stephenson, Sally L.; Gray, D. Fraser  
CS Department of Medicine, Queen Mary Hospital, Hong Kong, Peop. Rep. China  
SO N. Engl. J. Med. (1998), 339(2), 61-68  
CODEN: NEJMAG; ISSN: 0028-4793  
PB Massachusetts Medical Society  
DT Journal  
LA English

L10 ANSWER 133 OF 160 CAPLUS COPYRIGHT 2001 ACS  
AN 1998:471054 CAPLUS  
DN 129:225320  
TI Efficacy of lamivudine in controlling **hepatitis** B virus  
recurrence after liver transplantation  
AU Nery, Jose R.; Weppler, Deborah; Rodriguez, Miguel; Ruiz, Phillip;  
Schiff,

Eugene R.; Tzakis, Andreas G.  
 CS Department of Surgery, Division of Transplantation; School of Medicine,  
 University of Miami, Miami, FL, 33136, USA  
 SO Transplantation (1998), 65(12), 1615-1621  
 CODEN: TRPLAU; ISSN: 0041-1337  
 PB Williams & Wilkins  
 DT Journal  
 LA English

L10 ANSWER 134 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1998:436524 CAPLUS  
 DN 129:170141  
 TI Anti-**hepatitis** B virus activity and metabolism of  
 2',3'-dideoxy-2',3'-didehydro-.beta.-L(-)-5-fluorocytidine  
 AU Zhu, Yong-Lian; Dutschman, Ginger E.; Liu, Shwu-Huey; Bridges, Edward G.;  
 Cheng, Yung-Chi  
 CS Department Pharmacology, Yale University School Medicine, New Haven, CT,  
 06520, USA  
 SO Antimicrob. Agents Chemother. (1998), 42(7), 1805-1810  
 CODEN: AMACCQ; ISSN: 0066-4804  
 PB American Society for Microbiology  
 DT Journal  
 LA English

L10 ANSWER 135 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1998:384811 CAPLUS  
 DN 129:103844  
 TI Emergence and takeover of YMDD motif mutant **hepatitis** B virus  
 during long-term lamivudine therapy and re-takeover by wild type after  
 cessation of therapy  
 AU Chayama, Kazuaki; Suzuki, Yoshiyuki; Kobayashi, Masahiro; Kobayashi,  
 Mizuho; Tsubota, Akihito; Hashimoto, Michie; Miyano, Yukiko; Koike,  
 Hiromi; Kobayashi, Mariko; Koida, Isao; Arase, Yasuji; Saitoh, Satoshi;  
 Murashima, Naoya; Ikeda, Kenji; Kumada, Hiromitsu  
 CS Department of Gastroenterology, Memorial Institute for Medical Research,  
 Toranomon Hospital, Okinaka, Tokyo, 105, Japan  
 SO Hepatology (Philadelphia) (1998), 27(6), 1711-1716  
 CODEN: HPTLD9; ISSN: 0270-9139  
 PB W. B. Saunders Co.  
 DT Journal  
 LA English

L10 ANSWER 136 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1998:384808 CAPLUS  
 DN 129:157479  
 TI Identification and characterization of mutations in **hepatitis** B  
 virus resistant to lamivudine  
 AU Allen, Marchelle I.; Deslauriers, Manon; Andrews, C. Webster; Tipples,  
 Graham A.; Walters, Kathie-Anne; Tyrrell, David L. J.; Brown, Nathaniel;  
 Condreay, Lynn D.  
 CS Department of Virology, Glaxo Wellcome Inc., Research Triangle Park, NC,  
 27709-3398, USA  
 SO Hepatology (Philadelphia) (1998), 27(6), 1670-1677  
 CODEN: HPTLD9; ISSN: 0270-9139  
 PB W. B. Saunders Co.  
 DT Journal  
 LA English

Eugene R.; Tzakis, Andreas G.  
 CS Department of Surgery, Division of Transplantation; School of Medicine,  
 University of Miami, Miami, FL, 33136, USA  
 SO Transplantation (1998), 65(12), 1615-1621  
 CODEN: TRPLAU; ISSN: 0041-1337  
 PB Williams & Wilkins  
 DT Journal  
 LA English

L10 ANSWER 134 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1998:436524 CAPLUS  
 DN 129:170141  
 TI Anti-**hepatitis** B virus activity and metabolism of  
 2',3'-dideoxy-2',3'-didehydro-.beta.-L(-)-5-fluorocytidine  
 AU Zhu, Yong-Lian; Dutschman, Ginger E.; Liu, Shwu-Huey; Bridges, Edward G.;  
 Cheng, Yung-Chi  
 CS Department Pharmacology, Yale University School Medicine, New Haven, CT,  
 06520, USA  
 SO Antimicrob. Agents Chemother. (1998), 42(7), 1805-1810  
 CODEN: AMACCQ; ISSN: 0066-4804  
 PB American Society for Microbiology  
 DT Journal  
 LA English

L10 ANSWER 135 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1998:384811 CAPLUS  
 DN 129:103844  
 TI Emergence and takeover of YMDD motif mutant **hepatitis** B virus  
 during long-term lamivudine therapy and re-takeover by wild type after  
 cessation of therapy  
 AU Chayama, Kazuaki; Suzuki, Yoshiyuki; Kobayashi, Masahiro; Kobayashi,  
 Mizuho; Tsubota, Akihito; Hashimoto, Michie; Miyano, Yukiko; Koike,  
 Hiromi; Kobayashi, Mariko; Koida, Isao; Arase, Yasuji; Saitoh, Satoshi;  
 Murashima, Naoya; Ikeda, Kenji; Kumada, Hiromitsu  
 CS Department of Gastroenterology, Memorial Institute for Medical Research,  
 Toranomon Hospital, Okinaka, Tokyo, 105, Japan  
 SO Hepatology (Philadelphia) (1998), 27(6), 1711-1716  
 CODEN: HPTLD9; ISSN: 0270-9139  
 PB W. B. Saunders Co.  
 DT Journal  
 LA English

L10 ANSWER 136 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1998:384808 CAPLUS  
 DN 129:157479  
 TI Identification and characterization of mutations in **hepatitis** B  
 virus resistant to lamivudine  
 AU Allen, Marchelle I.; Deslauriers, Manon; Andrews, C. Webster; Tipples,  
 Graham A.; Walters, Kathie-Anne; Tyrrell, David L. J.; Brown, Nathaniel;  
 Condreay, Lynn D.  
 CS Department of Virology, Glaxo Wellcome Inc., Research Triangle Park, NC,  
 27709-3398, USA  
 SO Hepatology (Philadelphia) (1998), 27(6), 1670-1677  
 CODEN: HPTLD9; ISSN: 0270-9139  
 PB W. B. Saunders Co.  
 DT Journal  
 LA English

L10 ANSWER 137 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1998:289344 CAPLUS  
 DN 129:49250  
 TI Role of additional mutations outside the YMDD motif of **hepatitis**  
 B virus polymerase in L(-)SddC (3TC) resistance  
 AU Fu, Lei; Cheng, Yung-Chi  
 CS Department of Pharmacology, Yale University School of Medicine, New  
 Haven,  
 CT, 06520, USA  
 SO Biochem. Pharmacol. (1998), 55(10), 1567-1572  
 CODEN: BCPA6; ISSN: 0006-2952  
 PB Elsevier Science Inc.  
 DT Journal  
 LA English

L10 ANSWER 138 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1998:96111 CAPLUS  
 DN 128:225741  
 TI The **hepatitis** B virus M539V polymerase variation responsible for  
 3TC resistance also confers cross-resistance to other nucleoside analogs  
 AU Ladner, S. K.; Miller, T. J.; Otto, M. J.; King, R. W.  
 CS Avid Therapeutics, Philadelphia, PA, 19104, USA  
 SO Antiviral Chem. Chemother. (1998), 9(1), 65-72  
 CODEN: ACCHEH; ISSN: 0956-3202  
 PB International Medical Press  
 DT Journal  
 LA English

L10 ANSWER 139 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1998:23330 CAPLUS  
 DN 128:149229  
 TI Efficacy and safety of lamivudine on replication of recurrent  
**hepatitis** B after cadaveric renal transplantation  
 AU Rostaing, Lionel; Henry, Sabine; Cisterne, Jean-Marc; Duffaut, Michel;  
 Icart, Josette; Durand, Dominique  
 CS Multi-Organ Transplant Unit, Virology Laboratory, Toulouse University  
 Hospital, Toulouse, Fr.  
 SO Transplantation (1997), 64(11), 1624-1627  
 CODEN: TRPLAU; ISSN: 0041-1337  
 PB Williams & Wilkins  
 DT Journal  
 LA English

L10 ANSWER 140 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1997:718044 CAPLUS  
 DN 128:19356  
 TI Line probe assay [LiPA test strip] for genotyping and detecting  
**HBV** in blood serum  
 IN Stuyver, Lieven; Rossau, Rudi; Maertens, Geert  
 PA Innogenetics N.V., Belg.; Stuyver, Lieven; Rossau, Rudi; Maertens, Geert  
 SO PCT Int. Appl., 80 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9740193	A2	19971030	WO 1997-EP2002	19970421

L10 ANSWER 137 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1998:289344 CAPLUS  
 DN 129:49250  
 TI Role of additional mutations outside the YMDD motif of **hepatitis**  
 B virus polymerase in L(-)SddC (3TC) resistance  
 AU Fu, Lei; Cheng, Yung-Chi  
 CS Department of Pharmacology, Yale University School of Medicine, New  
 Haven,  
 CT, 06520, USA  
 SO Biochem. Pharmacol. (1998), 55(10), 1567-1572  
 CODEN: BCPA6; ISSN: 0006-2952  
 PB Elsevier Science Inc.  
 DT Journal  
 LA English

L10 ANSWER 138 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1998:96111 CAPLUS  
 DN 128:225741  
 TI The **hepatitis** B virus M539V polymerase variation responsible for  
 3TC resistance also confers cross-resistance to other nucleoside analogs  
 AU Ladner, S. K.; Miller, T. J.; Otto, M. J.; King, R. W.  
 CS Avid Therapeutics, Philadelphia, PA, 19104, USA  
 SO Antiviral Chem. Chemother. (1998), 9(1), 65-72  
 CODEN: ACCHEH; ISSN: 0956-3202  
 PB International Medical Press  
 DT Journal  
 LA English

L10 ANSWER 139 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1998:23330 CAPLUS  
 DN 128:149229  
 TI Efficacy and safety of lamivudine on replication of recurrent  
**hepatitis** B after cadaveric renal transplantation  
 AU Rostaing, Lionel; Henry, Sabine; Cisterne, Jean-Marc; Duffaut, Michel;  
 Icart, Josette; Durand, Dominique  
 CS Multi-Organ Transplant Unit, Virology Laboratory, Toulouse University  
 Hospital, Toulouse, Fr.  
 SO Transplantation (1997), 64(11), 1624-1627  
 CODEN: TRPLAU; ISSN: 0041-1337  
 PB Williams & Wilkins  
 DT Journal  
 LA English

L10 ANSWER 140 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1997:718044 CAPLUS  
 DN 128:19356  
 TI Line probe assay [LiPA test strip] for genotyping and detecting  
**HBV** in blood serum  
 IN Stuyver, Lieven; Rossau, Rudi; Maertens, Geert  
 PA Innogenetics N.V., Belg.; Stuyver, Lieven; Rossau, Rudi; Maertens, Geert  
 SO PCT Int. Appl., 80 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9740193	A2	19971030	WO 1997-EP2002	19970421

WO 9740193                      A3    19980507  
     W:    AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,  
           DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,  
           LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,  
           PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ,  
           VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
     RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB,  
           GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN,  
           ML, MR, NE, SN, TD, TG  
 AU 9727662                      A1    19971112                      AU 1997-27662                      19970421  
 EP 914472                      A2    19990512                      EP 1997-921677                      19970421  
     R:    AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
           IE, FI  
 PRAI EP 1996-870053                      19960419  
     WO 1997-EP2002                      19970421

L10 ANSWER 141 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1997:474419 CAPLUS  
 DN 127:130528  
 TI Lamivudine treatment of advanced and decompensated liver disease due to  
     **hepatitis B**  
 AU Van Thiel, David H.; Friedlander, Lois; Robert, R. N.; Kania, J.; Peter,  
     M.D.; Molloy, J.; Hassanein, Tarek; Wahlstrom, Eric; Faruki, Hawazin  
 CS Department of Medicine, University of Kentucky School of Medicine,  
     Lexington, KY, USA  
 SO Hepato-Gastroenterology (1997), 44(15), 808-812  
     CODEN: HEGAD4; ISSN: 0172-6390  
 PB H.G.E. Update Medical Publishing  
 DT Journal  
 LA English

L10 ANSWER 142 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1997:472373 CAPLUS  
 DN 127:130526  
 TI Synergistic inhibition of hepadnaviral replication by lamivudine in  
     combination with penciclovir in vitro  
 AU Colledge, Danni; Locarnini, Stephen; Shaw, Tim  
 CS Victorian Infectious Diseases Reference Laboratories, Fairfield Hospital,  
     Fairfield, 3078, Australia  
 SO Hepatology (Philadelphia) (1997), 26(1), 216-225  
     CODEN: HPTLD9; ISSN: 0270-9139  
 PB Saunders  
 DT Journal  
 LA English

L10 ANSWER 143 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1997:228422 CAPLUS  
 DN 126:271670  
 TI Liver transplantation and **hepatitis B**: treatment and prophylaxis  
     of reinfection with new **antiviral** agents  
 AU Krueger, Martin; Manns, Michael P.  
 CS Department of Gastroenterology and Hepatology, Medizinische Hannover,  
     Hannover, D-30623, Germany  
 SO Antiviral Ther. (1996), 1(Suppl. 4, Therapies for Viral Hepatitis), 71-75  
     CODEN: ANTHFA; ISSN: 1359-6535  
 PB International Medical Press  
 DT Journal; General Review  
 LA English

WO 9740193                      A3      19980507  
     W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,  
         DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,  
         LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,  
         PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ,  
         VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
     RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB,  
         GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN,  
         ML, MR, NE, SN, TD, TG  
 AU 9727662                      A1      19971112                      AU 1997-27662                      19970421  
 EP 914472                      A2      19990512                      EP 1997-921677                      19970421  
     R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
         IE, FI  
 PRAI EP 1996-870053                      19960419  
     WO 1997-EP2002                      19970421

L10 ANSWER 141 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1997:474419 CAPLUS  
 DN 127:130528  
 TI Lamivudine treatment of advanced and decompensated liver disease due to  
     **hepatitis B**  
 AU Van Thiel, David H.; Friedlander, Lois; Robert, R. N.; Kania, J.; Peter,  
     M.D.; Molloy, J.; Hassanein, Tarek; Wahlstrom, Eric; Faruki, Hawazin  
 CS Department of Medicine, University of Kentucky School of Medicine,  
     Lexington, KY, USA  
 SO Hepato-Gastroenterology (1997), 44(15), 808-812  
     CODEN: HEGAD4; ISSN: 0172-6390  
 PB H.G.E. Update Medical Publishing  
 DT Journal  
 LA English

L10 ANSWER 142 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1997:472373 CAPLUS  
 DN 127:130526  
 TI Synergistic inhibition of hepadnaviral replication by lamivudine in  
     combination with penciclovir in vitro  
 AU Colledge, Danni; Locarnini, Stephen; Shaw, Tim  
 CS Victorian Infectious Diseases Reference Laboratories, Fairfield Hospital,  
     Fairfield, 3078, Australia  
 SO Hepatology (Philadelphia) (1997), 26(1), 216-225  
     CODEN: HPTLD9; ISSN: 0270-9139  
 PB Saunders  
 DT Journal  
 LA English

L10 ANSWER 143 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1997:228422 CAPLUS  
 DN 126:271670  
 TI Liver transplantation and **hepatitis B**: treatment and prophylaxis  
     of reinfection with new **antiviral** agents  
 AU Krueger, Martin; Manns, Michael P.  
 CS Department of Gastroenterology and Hepatology, Medizinische Hannover,  
     Hannover, D-30623, Germany  
 SO Antiviral Ther. (1996), 1(Suppl. 4, Therapies for Viral Hepatitis), 71-75  
     CODEN: ANTHFA; ISSN: 1359-6535  
 PB International Medical Press  
 DT Journal; General Review  
 LA English



L10 ANSWER 144 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1997:189168 CAPLUS  
 DN 126:233148  
 TI Beneficial effect of lamivudine in recurrent **hepatitis** B after  
 liver transplantation  
 AU Ben-Ari, Ziv; Shmueli, Dan; Mor, Eitan; Shapira, Zaki; Tur-Kaspa, Ran  
 CS Departments of Transplantation and Surgery B, Rabin Medical Center, Liver  
 Institute and Internal Depat D, Petah Tiqva, 49 100, Israel  
 SO Transplantation (1997), 63(3), 393-403  
 CODEN: TRPLAU; ISSN: 0041-1337  
 PB Williams & Wilkins  
 DT Journal  
 LA English

L10 ANSWER 145 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1997:145208 CAPLUS  
 DN 126:139863  
 TI Stabilized nucleotides from nucleosides with anti-**hepatitis** B  
 virus activity, nucleosides and nucleotides for treatment of  
**hepatitis** B virus infection, and compound preparation  
 IN Schinazi, Raymond F.; Sommadossi, Jean-Pierre; Grosselin, Gilles; Imbach,  
 Jean-Louis  
 PA Emory University, USA; Uab Research Foundation; Centre National de la  
 Recherche Scientifique  
 SO PCT Int. Appl., 51PP  
 CODEN: PIXXD2  
 DT Patent  
 LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9640164	A1	19961219	WO 1996-US10026	19960607
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,				
SE	CA 2219132	AA	19961219	CA 1996-2219132	19960607
	AU 9661707	A1	19961230	AU 1996-61707	19960607
	AU 722214	B2	20000727		
	EP 831852	A1	19980401	EP 1996-919349	19960607
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, FI				
	JP 11507381	T2	19990629	JP 1996-502163	19960607
	US 6245749	B1	20010612	US 1998-112878	19980709
PRAI	US 1995-485716	A	19950607		
	US 1994-320461	B2	19941007		
	WO 1996-US10026	W	19960607		
OS	MARPAT 126:139863				

L10 ANSWER 146 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1997:100922 CAPLUS  
 DN 126:180871  
 TI Lamivudine is effective in suppressing **hepatitis** B virus DNA in  
 Chinese **hepatitis** B surface antigen carriers: a  
 placebo-controlled trial  
 AU Lai, Ching-Lung; Ching, Chi-Kong; Tung, Angus Kwong-Ming; Li, Eileen;  
 Young, John; Andrew, Hill; Wong, Benjamin Chun-Yu; Dent, Julie; Wu,  
 Pui-Chee

L10 ANSWER 144 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1997:189168 CAPLUS  
 DN 126:233148  
 TI Beneficial effect of lamivudine in recurrent **hepatitis** B after liver transplantation  
 AU Ben-Ari, Ziv; Shmueli, Dan; Mor, Eitan; Shapira, Zaki; Tur-Kaspa, Ran  
 CS Departments of Transplantation and Surgery B, Rabin Medical Center, Liver Institute and Internal Depat D, Petah Tiqva, 49 100, Israel  
 SO Transplantation (1997), 63(3), 393-403  
 CODEN: TRPLAU; ISSN: 0041-1337  
 PB Williams & Wilkins  
 DT Journal  
 LA English

L10 ANSWER 145 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1997:145208 CAPLUS  
 DN 126:139863  
 TI Stabilized nucleotides from nucleosides with anti-**hepatitis** B virus activity, nucleosides and nucleotides for treatment of **hepatitis** B virus infection, and compound preparation  
 IN Schinazi, Raymond F.; Sommadossi, Jean-Pierre; Grosselin, Gilles; Imbach, Jean-Louis  
 PA Emory University, USA; Uab Research Foundation; Centre National de la Recherche Scientifique  
 SO PCT Int. Appl., 51PP  
 CODEN: PIXXD2  
 DT Patent  
 LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9640164	A1	19961219	WO 1996-US10026	19960607
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2219132	AA	19961219	CA 1996-2219132	19960607
	AU 9661707	A1	19961230	AU 1996-61707	19960607
	AU 722214	B2	20000727		
	EP 831852	A1	19980401	EP 1996-919349	19960607
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 11507381	T2	19990629	JP 1996-502163	19960607
	US 6245749	B1	20010612	US 1998-112878	19980709
PRAI	US 1995-485716	A	19950607		
	US 1994-320461	B2	19941007		
	WO 1996-US10026	W	19960607		
OS	MARPAT 126:139863				

L10 ANSWER 146 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1997:100922 CAPLUS  
 DN 126:180871  
 TI Lamivudine is effective in suppressing **hepatitis** B virus DNA in Chinese **hepatitis** B surface antigen carriers: a placebo-controlled trial  
 AU Lai, Ching-Lung; Ching, Chi-Kong; Tung, Angus Kwong-Ming; Li, Eileen; Young, John; Andrew, Hill; Wong, Benjamin Chun-Yu; Dent, Julie; Wu, Pui-Chee

CS Department of Medicine, University of Hong Kong, Hong Kong  
 SO Hepatology (Philadelphia) (1997), 25(1), 241-244  
 CODEN: HPTLD9; ISSN: 0270-9139  
 PB Saunders  
 DT Journal  
 LA English

L10 ANSWER 147 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1997:92430 CAPLUS  
 DN 126:184874  
 TI Impact of complete inhibition of viral replication on the cellular immune response in chronic **hepatitis** B virus infection  
 AU Marinos, George; Naoumov, Nikolai V.; Williams, Roger  
 CS Institute of Liver Studies, King's College School of Medicine and Dentistry, London, UK  
 SO Hepatology (Philadelphia) (1996), 24(5), 991-995  
 CODEN: HPTLD9; ISSN: 0270-9139  
 PB Saunders  
 DT Journal  
 LA English

L10 ANSWER 148 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1997:8478 CAPLUS  
 DN 126:42321  
 TI Efficacy of lamivudine in chronic **hepatitis** B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation  
 AU Bain, Vincent G.; Kneteman, Norman M.; Ma, Mang M.; Gutfreund, Klaus; Shapiro, James A.; Fischer, Karl; Tipples, Graham; Lee, Helen; Jewell, Laurence D.; Tyrrell, D. Lorne  
 CS The Departments of Medicine, Surgery, Medical Microbiology and Immunology,  
 and Pathology, University of Alberta, Edmonton, AB, Can.  
 SO Transplantation (1996), 62(10), 1456-1462  
 CODEN: TRPLAU; ISSN: 0041-1337  
 PB Williams & Wilkins  
 DT Journal  
 LA English

L10 ANSWER 149 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1996:682645 CAPLUS  
 DN 125:316343  
 TI Effects of lamivudine on replication of **hepatitis** B virus in HIV-infected men  
 AU Benhamou, Yves; Katlama, Christine; Lunel, Françoise; Coutellier, Anne; Dohin, Elisabeth; Hamm, Nathalie; Tubiana, Roland; Herson, Serge; Poynard, Thierry; Opolon, Pietre  
 CS Groupe Hosp. Pitie-Salpetriere, Paris, Fr.  
 SO Ann. Intern. Med. (1996), 125(9), 705-712  
 CODEN: AIMEAS; ISSN: 0003-4819  
 DT Journal  
 LA English

L10 ANSWER 150 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1996:584863 CAPLUS  
 DN 125:237700  
 TI Selection of mutations in the **hepatitis** B virus polymerase

CS Department of Medicine, University of Hong Kong, Hong Kong  
 SO Hepatology (Philadelphia) (1997), 25(1), 241-244  
 CODEN: HPTLD9; ISSN: 0270-9139  
 PB Saunders  
 DT Journal  
 LA English

L10 ANSWER 147 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1997:92430 CAPLUS  
 DN 126:184874  
 TI Impact of complete inhibition of viral replication on the cellular immune response in chronic **hepatitis** B virus infection  
 AU Marinos, George; Naoumov, Nikolai V.; Williams, Roger  
 CS Institute of Liver Studies, King's College School of Medicine and Dentistry, London, UK  
 SO Hepatology (Philadelphia) (1996), 24(5), 991-995  
 CODEN: HPTLD9; ISSN: 0270-9139  
 PB Saunders  
 DT Journal  
 LA English

L10 ANSWER 148 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1997:8478 CAPLUS  
 DN 126:42321  
 TI Efficacy of lamivudine in chronic **hepatitis** B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation  
 AU Bain, Vincent G.; Kneteman, Norman M.; Ma, Mang M.; Gutfreund, Klaus; Shapiro, James A.; Fischer, Karl; Tipples, Graham; Lee, Helen; Jewell, Laurence D.; Tyrrell, D. Lorne  
 CS The Departments of Medicine, Surgery, Medical Microbiology and Immunology, and Pathology, University of Alberta, Edmonton, AB, Can.  
 SO Transplantation (1996), 62(10), 1456-1462  
 CODEN: TRPLAU; ISSN: 0041-1337  
 PB Williams & Wilkins  
 DT Journal  
 LA English

L10 ANSWER 149 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1996:682645 CAPLUS  
 DN 125:316343  
 TI Effects of lamivudine on replication of **hepatitis** B virus in HIV-infected men  
 AU Benhamou, Yves; Katlama, Christine; Lunel, Françoise; Coutellier, Anne; Dohin, Elisabeth; Hamm, Nathalie; Tubiana, Roland; Herson, Serge; Poynard, Thierry; Opolon, Pietre  
 CS Groupe Hosp. Pitie-Salpetriere, Paris, Fr.  
 SO Ann. Intern. Med. (1996), 125(9), 705-712  
 CODEN: AIMEAS; ISSN: 0003-4819  
 DT Journal  
 LA English

L10 ANSWER 150 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1996:584863 CAPLUS  
 DN 125:237700  
 TI Selection of mutations in the **hepatitis** B virus polymerase

during therapy of transplant recipients with lamivudine

AU Ling, Roger; Mutimer, David; Ahmed, Monz; Boxall, Elizabeth H.; Elias, Elwyn; Dusheiko, Geoffrey M.; Harrison, Tim J.

CS School Medicine, Royal Free Hospital, London, NW3 2PF, UK

SO Hepatology (Philadelphia) (1996), 24(3), 711-713

CODEN: HPTLD9; ISSN: 0270-9139

DT Journal

LA English

L10 ANSWER 151 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1996:503607 CAPLUS

DN 125:211868

TI Anti-HIV and anti-**HBV** activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative

CF 1109

AU Balzarini, Jan; Wedgwood, O.; Kruining, J.; Pelemans, Heidi; Heijtkink, R.;

De Clercq, Erik; McGuigan, C.

CS Rega Inst. Med. Res., Kathol. Univ. Leuven, Louvain, B-3000, Belg.

SO Biochem. Biophys. Res. Commun. (1996), 225(2), 363-369

CODEN: BBRCA9; ISSN: 0006-291X

DT Journal

LA English

L10 ANSWER 152 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1996:330477 CAPLUS

DN 125:75411

TI DNA polymerase activity of **hepatitis B** virus particles: differential inhibition by L-enantiomers of nucleotide analogs

AU Davis, Michelle G.; Wilson, Jeanne E.; VanDraanen, Nanine A.; Miller, Wayne H.; Freeman, George A.; Daluge, Susan M.; Boyd, Frank L.;

Aulabaugh, Ann E.; Painter, George R.; et al.

CS Glaxo Wellcome Inc., Research Triangle Park, NC 27709, USA

SO Antiviral Res. (1996), 30(2,3), 133-145

CODEN: ARSRDR; ISSN: 0166-3542

DT Journal

LA English

L10 ANSWER 153 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1996:200483 CAPLUS

DN 124:278119

TI In vitro evaluation of combination therapies against **hepatitis B** virus replication

AU Korba, Brent E.

CS Georgetown University, Division of Molecular Virology and Immunology, Rockville, USA

SO Antiviral Res. (1996), 29(1), 49-51

CODEN: ARSRDR; ISSN: 0166-3542

DT Journal

LA English

L10 ANSWER 154 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1996:143766 CAPLUS

DN 124:249564

TI Pharmacokinetics of (-)-2'-3'-dideoxy-3'-thiacytidine in woodchucks

AU Rajagopalan, Prabhu; Boudinot, F. Douglas; Chu, Chunk G.; Tennant, Bud C.;

during therapy of transplant recipients with lamivudine  
AU Ling, Roger; Mutimer, David; Ahmed, Monz; Boxall, Elizabeth H.; Elias,  
Elwyn; Dusheiko, Geoffrey M.; Harrison, Tim J.  
CS School Medicine, Royal Free Hospital, London, NW3 2PF, UK  
SO Hepatology (Philadelphia) (1996), 24(3), 711-713  
CODEN: HPTLD9; ISSN: 0270-9139  
DT Journal  
LA English

L10 ANSWER 151 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1996:503607 CAPLUS

DN 125:211868

TI Anti-HIV and anti-**HBV** activity and resistance profile of  
2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate  
derivative

CF 1109

AU Balzarini, Jan; Wedgwood, O.; Kruining, J.; Pelemans, Heidi; Heijtkink,  
R.;

De Clercq, Erik; McGuigan, C.

CS Rega Inst. Med. Res., Kathol. Univ. Leuven, Louvain, B-3000, Belg.

SO Biochem. Biophys. Res. Commun. (1996), 225(2), 363-369

CODEN: BBRC9; ISSN: 0006-291X

DT Journal

LA English

L10 ANSWER 152 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1996:330477 CAPLUS

DN 125:75411

TI DNA polymerase activity of **hepatitis B** virus particles:  
differential inhibition by L-enantiomers of nucleotide analogs

AU Davis, Michelle G.; Wilson, Jeanne E.; VanDraanen, Nanine A.; Miller,  
Wayne H.; Freeman, George A.; Daluge, Susan M.; Boyd, Frank L.;  
Aulabaugh,

Ann E.; Painter, George R.; et al.

CS Glaxo Wellcome Inc., Research Triangle Park, NC 27709, USA

SO Antiviral Res. (1996), 30(2,3), 133-145

CODEN: ARSRDR; ISSN: 0166-3542

DT Journal

LA English

L10 ANSWER 153 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1996:200483 CAPLUS

DN 124:278119

TI In vitro evaluation of combination therapies against **hepatitis B**  
virus replication

AU Korba, Brent E.

CS Georgetown University, Division of Molecular Virology and Immunology,  
Rockville, USA

SO Antiviral Res. (1996), 29(1), 49-51

CODEN: ARSRDR; ISSN: 0166-3542

DT Journal

LA English

L10 ANSWER 154 OF 160 CAPLUS COPYRIGHT 2001 ACS

AN 1996:143766 CAPLUS

DN 124:249564

TI Pharmacokinetics of (-)-2'-3'-dideoxy-3'-thiacytidine in woodchucks

AU Rajagopalan, Prabhu; Boudinot, F. Douglas; Chu, Chunk G.; Tennant, Bud  
C.;

Baldwin, Betty H.; Schinazi, Raymond F.  
 CS Coll. Pharm., Univ. Georgia, Athens, GA, 30602, USA  
 SO Antimicrob. Agents Chemother. (1996), 40(3), 642-5  
 CODEN: AMACCQ; ISSN: 0066-4804  
 DT Journal  
 LA English

L10 ANSWER 155 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1996:49895 CAPLUS  
 DN 124:164383  
 TI A preliminary trial of lamivudine for chronic **hepatitis B** infection  
 AU Dienstag, Jules L.; Perrillo, Robert P.; Schiff, Eugene R.; Bartholomew, Maria; Vicary, Catherine; Rubin, Marc  
 CS Dep. Med., Harvard Med. Sch., Boston, MA, USA  
 SO N. Engl. J. Med. (1995), 333(25), 1657-61  
 CODEN: NEJMAG; ISSN: 0028-4793  
 DT Journal  
 LA English

L10 ANSWER 156 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1995:875381 CAPLUS  
 DN 124:193342  
 TI Phosphatidyl-2',3'-dideoxy-3'-thiacytidine: synthesis and **antiviral** activity in **hepatitis B**- and HIV-1-infected cells  
 AU Xie, Hong; Voronkov, Michael; Liotta, Dennis C.; Korba, Brent A.; Schinazi, Raymond F.; Richman, Douglas D.; Hostetler, Karl Y.  
 CS Department of Medicine, University of California, San Diego, La Jolla, CA, 92093, USA  
 SO Antiviral Res. (1995), 28(2), 113-20  
 CODEN: ARSRDR; ISSN: 0166-3542  
 DT Journal  
 LA English

L10 ANSWER 157 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1994:499776 CAPLUS  
 DN 121:99776  
 TI Enantiomerically pure .beta.-D-dioxolane nucleosides with selective anti-**hepatitis B** virus (**HBV**) activity  
 IN Schinazi, Raymond P.  
 PA Emory University, USA  
 SO PCT Int. Appl., 52 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9409793	A1	19940511	WO 1993-US10348	19931028
	W: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5444063	A	19950822	US 1992-967460	19921028
	AU 9455419	A1	19940524	AU 1994-55419	19931028
	AU 693079	B2	19980625		

Baldwin, Betty H.; Schinazi, Raymond F.  
 CS Coll. Pharm., Univ. Georgia, Athens, GA, 30602, USA  
 SO Antimicrob. Agents Chemother. (1996), 40(3), 642-5  
 CODEN: AMACQ; ISSN: 0066-4804  
 DT Journal  
 LA English

L10 ANSWER 155 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1996:49895 CAPLUS  
 DN 124:164383  
 TI A preliminary trial of lamivudine for chronic **hepatitis B** infection  
 AU Dienstag, Jules L.; Perrillo, Robert P.; Schiff, Eugene R.; Bartholomew, Maria; Vicary, Catherine; Rubin, Marc  
 CS Dep. Med., Harvard Med. Sch., Boston, MA, USA  
 SO N. Engl. J. Med. (1995), 333(25), 1657-61  
 CODEN: NEJMAG; ISSN: 0028-4793  
 DT Journal  
 LA English

L10 ANSWER 156 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1995:875381 CAPLUS  
 DN 124:193342  
 TI Phosphatidyl-2',3'-dideoxy-3'-thiacytidine: synthesis and **antiviral** activity in **hepatitis B**- and HIV-1-infected cells  
 AU Xie, Hong; Voronkov, Michael; Liotta, Dennis C.; Korba, Brent A.; Schinazi, Raymond F.; Richman, Douglas D.; Hostetler, Karl Y.  
 CS Department of Medicine, University of California, San Diego, La Jolla, CA, 92093, USA  
 SO Antiviral Res. (1995), 28(2), 113-20  
 CODEN: ARSRDR; ISSN: 0166-3542  
 DT Journal  
 LA English

L10 ANSWER 157 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN 1994:499776 CAPLUS  
 DN 121:99776  
 TI Enantiomerically pure .beta.-D-dioxolane nucleosides with selective anti-**hepatitis B** virus (**HBV**) activity  
 IN Schinazi, Raymond P.  
 PA Emory University, USA  
 SO PCT Int. Appl., 52 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9409793	A1	19940511	WO 1993-US10348	19931028
	W: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5444063	A	19950822	US 1992-967460	19921028
	AU 9455419	A1	19940524	AU 1994-55419	19931028
	AU 693079	B2	19980625		



EP 666749                    A1    19950816                    EP 1994-900424    19931028  
 EP 666749                    B1    19980415  
       R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,  
 SE  
       JP 08507286            T2    19960806                    JP 1993-511314    19931028  
       JP 3117217            B2    20001211                    JP 1994-511314    19931028  
 PRAI US 1992-967460        A    19921028  
       US 1990-622762        A2    19901205  
       US 1992-935515        B2    19920825  
       WO 1993-US10348       W    19931028  
 OS    MARPAT 121:99776

L10 ANSWER 158 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN    1994:289465 CAPLUS  
 DN    120:289465  
 TI    Influence of stereochemistry on **antiviral** activities and  
       resistance profiles of dideoxycytidine nucleosides  
 AU    Van Draanen, Nanine A.; Tisdale, Margaret; Parry, Nigel R.; Jansen,  
       Robert; Dornsife, Ronna E.; Tuttle, Joel V.; Averett, Devron R.;  
 Koszalka,  
       George W.  
 CS    Div. Exp. Therapy, Burroughs Wellcome Co., Research Triangle Park, NC,  
       27709, USA  
 SO    Antimicrob. Agents Chemother. (1994), 38(4), 868-71  
       CODEN: AMACQ; ISSN: 0066-4804  
 DT    Journal  
 LA    English

L10 ANSWER 159 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN    1993:93802 CAPLUS  
 DN    118:93802  
 TI    The anti-**hepatitis** B virus activities, cytotoxicities, and  
       anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-  
       (hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine  
 AU    Furman, Phillip A.; Davis, Michelle; Liotta, Dennis C.; Paff, Melanie;  
       Frick, Lloyd W.; Nelson, Donald J.; Dornsife, Ronna E.; Wurster, J. A.;  
       Wilson, Lawrence J.; et al.  
 CS    Div. Virol., Burroughs Wellcome Co., Research Triangle Park, NC, 27709,  
       USA  
 SO    Antimicrob. Agents Chemother. (1992), 36(12), 2686-92  
       CODEN: AMACQ; ISSN: 0066-4804  
 DT    Journal  
 LA    English

L10 ANSWER 160 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN    1992:194772 CAPLUS  
 DN    116:194772  
 TI    Synthesis of enantiomerically pure (2'R,5'S)-(-)-1-(2-  
       hydroxymethyloxathiolan-5-yl)cytosine as a potent **antiviral**  
       agent against **hepatitis** B virus (HBV) and human  
       immunodeficiency virus (HIV)  
 AU    Beach, J. Warren; Jeong, Lak S.; Alves, Antonio J.; Pohl, Douglas; Kim,  
       Hea O.; Chang, Chien Neng; Doong, Shin Lian; Schinazi, Raymond F.; Cheng,  
       Yung Chi; Chu, Chung K.  
 CS    Coll. Pharm., Univ. Georgia, Athens, GA, 30602, USA  
 SO    J. Org. Chem. (1992), 57(8), 2217-19  
       CODEN: JOCEAH; ISSN: 0022-3263  
 DT    Journal

EP 666749                    A1    19950816                    EP 1994-900424    19931028  
 EP 666749                    B1    19980415  
       R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,  
 SE  
       JP 08507286            T2    19960806                    JP 1993-511314    19931028  
       JP 3117217            B2    20001211                    JP 1994-511314    19931028  
 PRAI US 1992-967460        A    19921028  
       US 1990-622762        A2    19901205  
       US 1992-935515        B2    19920825  
       WO 1993-US10348       W    19931028  
 OS    MARPAT 121:99776  
  
 L10 ANSWER 158 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN    1994:289465 CAPLUS  
 DN    120:289465  
 TI    Influence of stereochemistry on **antiviral** activities and  
       resistance profiles of dideoxycytidine nucleosides  
 AU    Van Draanen, Nanine A.; Tisdale, Margaret; Parry, Nigel R.; Jansen,  
       Robert; Dornsife, Ronna E.; Tuttle, Joel V.; Averett, Devron R.;  
       Koszalka,  
       George W.  
 CS    Div. Exp. Therapy, Burroughs Wellcome Co., Research Triangle Park, NC,  
       27709, USA  
 SO    Antimicrob. Agents Chemother. (1994), 38(4), 868-71  
       CODEN: AMACCQ; ISSN: 0066-4804  
 DT    Journal  
 LA    English  
  
 L10 ANSWER 159 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN    1993:93802 CAPLUS  
 DN    118:93802  
 TI    The anti-**hepatitis** B virus activities, cytotoxicities, and  
       anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-  
       (hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine  
 AU    Furman, Phillip A.; Davis, Michelle; Liotta, Dennis C.; Paff, Melanie;  
       Frick, Lloyd W.; Nelson, Donald J.; Dornsife, Ronna E.; Wurster, J. A.;  
       Wilson, Lawrence J.; et al.  
 CS    Div. Virol., Burroughs Wellcome Co., Research Triangle Park, NC, 27709,  
       USA  
 SO    Antimicrob. Agents Chemother. (1992), 36(12), 2686-92  
       CODEN: AMACCQ; ISSN: 0066-4804  
 DT    Journal  
 LA    English  
  
 L10 ANSWER 160 OF 160 CAPLUS COPYRIGHT 2001 ACS  
 AN    1992:194772 CAPLUS  
 DN    116:194772  
 TI    Synthesis of enantiomerically pure (2'R,5'S)-(-)-1-(2-  
       hydroxymethyloxathiolan-5-yl)cytosine as a potent **antiviral**  
       agent against **hepatitis** B virus (HBV) and human  
       immunodeficiency virus (HIV)  
 AU    Beach, J. Warren; Jeong, Lak S.; Alves, Antonio J.; Pohl, Douglas; Kim,  
       Hea O.; Chang, Chien Neng; Doong, Shin Lian; Schinazi, Raymond F.; Cheng,  
       Yung Chi; Chu, Chung K.  
 CS    Coll. Pharm., Univ. Georgia, Athens, GA, 30602, USA  
 SO    J. Org. Chem. (1992), 57(8), 2217-19  
       CODEN: JOCEAH; ISSN: 0022-3263  
 DT    Journal

LA English  
OS CASREACT 116:194772

=> d his

(FILE 'HOME' ENTERED AT 11:59:11 ON 27 SEP 2001)

FILE 'REGISTRY' ENTERED AT 11:59:22 ON 27 SEP 2001

E DEOXYNOJIRIMYCIN

L1 32 S E1-E3

L2 10 S 3TC

FILE 'CAPLUS' ENTERED AT 12:01:58 ON 27 SEP 2001

E HEPATITIS

L3 31704 S E3

L4 4491 S HBV

L5 751 S L1

L6 1070 S L2

L7 16 S L5 AND L6

L8 271 S L6 AND L3

L9 176 S L8 AND L4

L10 160 S L9 AND ANTIVIRAL

=> s 15 and 13

L11 19 L5 AND L3

=> d l11 1-19

L11 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2001:677355 CAPLUS

DN 135:195748

TI Process for the synthesis of aza sugars having biological activity

IN Lopes, Claudio Cerqueira; Lopes, Rosangela Sabbatini Capella; Matos, Carlos Roberto Ribeiro

PA Brazil

SO Braz. Pedido PI, 56 pp.

CODEN: BPXXDX

DT Patent

LA Portuguese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	BR 9902585	A	20000926	BR 1999-2585	19990211

L11 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2001:617821 CAPLUS

DN 135:175348

TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating **hepatitis** virus infections

IN Mueller, Richard A.; Bryant, Martin L.

PA Pharmacia Corporation, USA

SO PCT Int. Appl., 116 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
--	------------	------	------	-----------------	------

LA English  
OS CASREACT 116:194772

=> d his

(FILE 'HOME' ENTERED AT 11:59:11 ON 27 SEP 2001)

FILE 'REGISTRY' ENTERED AT 11:59:22 ON 27 SEP 2001

E DEOXYNOJIRIMYCIN

L1 32 S E1-E3

L2 10 S 3TC

FILE 'CAPLUS' ENTERED AT 12:01:58 ON 27 SEP 2001

E HEPATITIS

L3 31704 S E3

L4 4491 S HBV

L5 751 S L1

L6 1070 S L2

L7 16 S L5 AND L6

L8 271 S L6 AND L3

L9 176 S L8 AND L4

L10 160 S L9 AND ANTIVIRAL

=> s 15 and 13

L11 19 L5 AND L3

=> d l11 1-19

L11 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2001:677355 CAPLUS

DN 135:195748

TI Process for the synthesis of aza sugars having biological activity

IN Lopes, Claudio Cerqueira; Lopes, Rosangela Sabbatini Capella; Matos, Carlos Roberto Ribeiro

PA Brazil

SO Braz. Pedido PI, 56 pp.

CODEN: BPXXDX

DT Patent

LA Portuguese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	BR 9902585	A	20000926	BR 1999-2585	19990211

L11 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2001:617821 CAPLUS

DN 135:175348

TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating **hepatitis** virus infections

IN Mueller, Richard A.; Bryant, Martin L.

PA Pharmacia Corporation, USA

SO PCT Int. Appl., 116 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
--	------------	------	------	-----------------	------

-----  
 PI WO 2001060366 A1 20010823 WO 2001-US4512 20010213  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,  
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,  
 YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 PRAI US 2000-182362 P 20000214

RE.CNT 9

RE

- (1) Block, T; NATURE MEDICINE 1998, V4(5), P610 CAPLUS
  - (2) Block, T; PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA 1994, V91(6), P2235 CAPLUS
  - (3) Dwek, R; WO 9835685 A 1998 CAPLUS
  - (4) Mueller, R; WO 9940916 A 1999 CAPLUS
  - (5) Mueller, R; WO 0047198 A 2000 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2001:338762 CAPLUS

DN 134:362292

TI Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile

IN Farr, Spencer

PA Phase-1 Molecular Toxicology, USA

SO PCT Int. Appl., 222 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001032928	A2	20010510	WO 2000-US30474	20001103
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				
	HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				
	LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				
	SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,				
	YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 1999-165398	P	19991105		
	US 2000-196571	P	20000411		

L11 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2001:300514 CAPLUS

DN 134:331617

TI Oil-in-water emulsion compositions for polyfunctional active ingredients

IN Chen, Feng-jing; Patel, Mahesh V.

PA Lipocine, Inc., USA

SO PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DT Patent

-----  
 PI WO 2001060366 A1 20010823 WO 2001-US4512 20010213  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,  
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,  
 YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 PRAI US 2000-182362 P 20000214

RE.CNT 9

RE

- (1) Block, T; NATURE MEDICINE 1998, V4(5), P610 CAPLUS
  - (2) Block, T; PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA 1994, V91(6), P2235 CAPLUS
  - (3) Dwek, R; WO 9835685 A 1998 CAPLUS
  - (4) Mueller, R; WO 9940916 A 1999 CAPLUS
  - (5) Mueller, R; WO 0047198 A 2000 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2001:338762 CAPLUS

DN 134:362292

TI Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile

IN Farr, Spencer

PA Phase-1 Molecular Toxicology, USA

SO PCT Int. Appl., 222 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001032928	A2	20010510	WO 2000-US30474	20001103
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				
	HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				
	LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				
	SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,				
	YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 1999-165398	P	19991105		
	US 2000-196571	P	20000411		

L11 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2001:300514 CAPLUS

DN 134:331617

TI Oil-in-water emulsion compositions for polyfunctional active ingredients

IN Chen, Feng-jing; Patel, Mahesh V.

PA Lipocine, Inc., USA

SO PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001028555	A1	20010426	WO 2000-US28835	20001018
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRAI US 1999-420159 A 19991018

RE.CNT 6

RE

- (1) Bistriani; US 4871768 A 1989 CAPLUS
- (2) Demichele; US 5661180 A 1997 CAPLUS
- (3) Demichele; US 6013665 A 2000 CAPLUS
- (4) Demichele; US 6130244 A 2000 CAPLUS
- (5) Demichele; US 6160007 A 2000 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2001:114972 CAPLUS

DN 134:163282

TI Preparation of long chain N-alkyl amino and imino alditols and oxa-derivatives as antiviral agents

IN Zitzmann, Nicole; Butters, Terry D.; Platt, Frances M.; Carrouee, Sandra; Jacob, Gary S.; Picker, Donald H.; Fleet, George W. J.; Dwek, Raymond A.

PA UK

SO PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001010429	A2	20010215	WO 2000-US21732	20000810
	WO 2001010429	A3	20010816		
	W:	AU, BR, CA, CN, IN, JP, KR, US			
	RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
	AU 2001018401	A5	20010305	AU 2001-18401	20000810
PRAI	US 1999-148101	P	19990810		
	US 2000-198621	P	20000420		
	WO 2000-US21732	W	20000810		
OS	MARPAT 134:163282				

L11 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2001:100967 CAPLUS

DN 134:141721

TI N-Substituted glucamine compounds for treating hepatitis virus infections

IN Mueller, Richard A.; Bryant, Martin L.; Partis, Richard A.

PA G.D. Searle & Co., USA

SO PCT Int. Appl., 148 pp.

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001028555	A1	20010426	WO 2000-US28835	20001018
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRAI US 1999-420159 A 19991018

RE.CNT 6

RE

(1) Bistrrian; US 4871768 A 1989 CAPLUS

(2) Demichele; US 5661180 A 1997 CAPLUS

(3) Demichele; US 6013665 A 2000 CAPLUS

(4) Demichele; US 6130244 A 2000 CAPLUS

(5) Demichele; US 6160007 A 2000 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2001:114972 CAPLUS

DN 134:163282

TI Preparation of long chain N-alkyl amino and imino alditols and oxa-derivatives as antiviral agents

IN Zitzmann, Nicole; Butters, Terry D.; Platt, Frances M.; Carrouee, Sandra; Jacob, Gary S.; Picker, Donald H.; Fleet, George W. J.; Dwek, Raymond A.

PA UK

SO PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001010429	A2	20010215	WO 2000-US21732	20000810
	WO 2001010429	A3	20010816		
	W:	AU, BR, CA, CN, IN, JP, KR, US			
	RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
	AU 2001018401	A5	20010305	AU 2001-18401	20000810
PRAI	US 1999-148101	P	19990810		
	US 2000-198621	P	20000420		
	WO 2000-US21732	W	20000810		
OS	MARPAT 134:163282				

L11 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2001:100967 CAPLUS

DN 134:141721

TI N-Substituted glucamine compounds for treating **hepatitis** virus infections

IN Mueller, Richard A.; Bryant, Martin L.; Partis, Richard A.

PA G.D. Searle & Co., USA

SO PCT Int. Appl., 148 pp.



CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001008672	A2	20010208	WO 2000-US3816	20000214
	W:				
	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,				
	CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,				
	IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,				
	MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,				
	SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,				
	AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,				
	DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,				
	CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 1999-119836	P	19990212		
	US 1999-119858	P	19990212		
OS	MARPAT 134:141721				

L11 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2000:573657 CAPLUS

DN 133:172150

TI Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating

**hepatitis** virus infections

IN Mueller, Richard A.; Bryant, Martin L.; Partis, Richard A.

PA G.D. Searle & Co., USA

SO PCT Int. Appl., 170 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000047198	A2	20000817	WO 2000-US3768	20000214
	WO 2000047198	A3	20010215		
	W:				
	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,				
	CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,				
	IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,				
	MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,				
	SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,				
	AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,				
	DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,				
	CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 1999-119722	P	19990212		
	US 1999-119856	P	19990212		
OS	MARPAT 133:172150				

L11 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2000:545931 CAPLUS

DN 133:346609

TI High-Performance Cation-Exchange Chromatography and Pulsed Amperometric Detection for the Separation, Detection, and Quantitation of N-Alkylated Imino Sugars in Biological Samples

AU Mellor, H. R.; Adam, A.; Platt, F. M.; Dwek, R. A.; Butters, T. D.

CS Oxford Glycobiology Institute, Dep. Biochem., University of Oxford,

CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001008672	A2	20010208	WO 2000-US3816	20000214
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 1999-119836	P	19990212		
	US 1999-119858	P	19990212		
OS	MARPAT 134:141721				

L11 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2000:573657 CAPLUS

DN 133:172150

TI Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating

**hepatitis** virus infections

IN Mueller, Richard A.; Bryant, Martin L.; Partis, Richard A.

PA G.D. Searle & Co., USA

SO PCT Int. Appl., 170 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000047198	A2	20000817	WO 2000-US3768	20000214
	WO 2000047198	A3	20010215		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 1999-119722	P	19990212		
	US 1999-119856	P	19990212		
OS	MARPAT 133:172150				

L11 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2000:545931 CAPLUS

DN 133:346609

TI High-Performance Cation-Exchange Chromatography and Pulsed Amperometric Detection for the Separation, Detection, and Quantitation of N-Alkylated Imino Sugars in Biological Samples

AU Mellor, H. R.; Adam, A.; Platt, F. M.; Dwek, R. A.; Butters, T. D.

CS Oxford Glycobiology Institute, Dep. Biochem., University of Oxford,

Oxford, OX1 3QU, UK  
SO Anal. Biochem. (2000), 284(1), 136-142  
CODEN: ANBCA2; ISSN: 0003-2697

PB Academic Press

DT Journal

LA English

RE.CNT 14

RE

- (1) Andersson, U; Biochem Pharmacol 2000, V59, P821 CAPLUS
- (2) Block, T; Nature Med 1998, V4, P610 CAPLUS
- (3) Butters, T; Tetrahedron: Asymmetry 2000, V11, P113 CAPLUS
- (4) Hardy, M; Proc Natl Acad Sci USA 1988, V85, P3289 CAPLUS
- (5) Jeyakumar, M; Proc Natl Acad Sci USA 1999, V96, P6388 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2000:172843 CAPLUS

DN 132:175813

TI Method using an N-alkyl derivative of 1,5-dideoxy-1,5-imino-D-glucitol  
for

inhibiting **hepatitis** B virus

IN Block, Timothy M.; Blumberg, Baruch S.; Dwek, Raymond A.

PA G. D. Searle & Co., USA

SO U.S., 14 pp., Cont.-in-part of U.S. Ser. No. 181,519, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6037351	A	20000314	US 1996-676153	19960711
	WO 9519172	A1	19950720	WO 1994-US14548	19941223
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ,				
VN	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
PRAI	US 1994-181519		19940113		
	WO 1994-US14548		19941223		

RE.CNT 21

RE

- (1) Block; Proc Natl Acad Sci USA 1994, V91, P2235 CAPLUS
- (3) Fleet; US 4849430 1989 CAPLUS
- (4) Fleet; FEBS Lett 1988, V237, P128 CAPLUS
- (5) Ganem; Chemtracts:Organic Chem 1994, V7(2), P106 CAPLUS
- (10) Jacob; US 4957926 1990 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 1999:685007 CAPLUS

DN 132:18513

TI Imino sugars inhibit the formation and secretion of bovine viral diarrhea  
virus, a pestivirus model of **hepatitis** C virus: implications for  
the development of broad spectrum anti-**hepatitis** virus agents

AU Zitzmann, Nicole; Mehta, Anand S.; Carrouee, Sandra; Butters, Terry D.;  
Platt, Frances M.; McCauley, John; Blumberg, Baruch S.; Dwek, Raymond A.;

Oxford, OX1 3QU, UK  
SO Anal. Biochem. (2000), 284(1), 136-142  
CODEN: ANBCA2; ISSN: 0003-2697

PB Academic Press

DT Journal

LA English

RE.CNT 14

RE

- (1) Andersson, U; Biochem Pharmacol 2000, V59, P821 CAPLUS
- (2) Block, T; Nature Med 1998, V4, P610 CAPLUS
- (3) Butters, T; Tetrahedron: Asymmetry 2000, V11, P113 CAPLUS
- (4) Hardy, M; Proc Natl Acad Sci USA 1988, V85, P3289 CAPLUS
- (5) Jeyakumar, M; Proc Natl Acad Sci USA 1999, V96, P6388 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 2000:172843 CAPLUS

DN 132:175813

TI Method using an N-alkyl derivative of 1,5-dideoxy-1,5-imino-D-glucitol  
for

inhibiting **hepatitis** B virus

IN Block, Timothy M.; Blumberg, Baruch S.; Dwek, Raymond A.

PA G. D. Searle & Co., USA

SO U.S., 14 pp., Cont.-in-part of U.S. Ser. No. 181,519, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6037351	A	20000314	US 1996-676153	19960711
	WO 9519172	A1	19950720	WO 1994-US14548	19941223
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ,				
VN	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
PRAI	US 1994-181519		19940113		
	WO 1994-US14548		19941223		

RE.CNT 21

RE

- (1) Block; Proc Natl Acad Sci USA 1994, V91, P2235 CAPLUS
- (3) Fleet; US 4849430 1989 CAPLUS
- (4) Fleet; FEBS Lett 1988, V237, P128 CAPLUS
- (5) Ganem; Chemtracts:Organic Chem 1994, V7(2), P106 CAPLUS
- (10) Jacob; US 4957926 1990 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 1999:685007 CAPLUS

DN 132:18513

TI Imino sugars inhibit the formation and secretion of bovine viral diarrhea  
virus, a pestivirus model of **hepatitis** C virus: implications for  
the development of broad spectrum anti-**hepatitis** virus agents

AU Zitzmann, Nicole; Mehta, Anand S.; Carrouee, Sandra; Butters, Terry D.;  
Platt, Frances M.; McCauley, John; Blumberg, Baruch S.; Dwek, Raymond A.;

Block, Timothy M.  
 CS The Glycobiology Institute, Department of Biochemistry, Oxford  
 University,  
 Oxford, OX1 3QU, UK  
 SO Proc. Natl. Acad. Sci. U. S. A. (1999), 96(21), 11878-11882  
 CODEN: PNASA6; ISSN: 0027-8424  
 PB National Academy of Sciences  
 DT Journal  
 LA English  
 RE.CNT 21  
 RE

- (2) Block, T; Nat Med 1998, V4, P610 CAPLUS
  - (3) Block, T; Proc Natl Acad Sci USA 1994, V91, P2235 CAPLUS
  - (4) Chambers, T; Annu Rev Microbiol 1990, V44, P649 CAPLUS
  - (5) Choukhi, A; J Virol 1998, V72, P3851 CAPLUS
  - (7) Dubuisson, J; J Virol 1994, V68, P6147 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2001 ACS  
 AN 1999:529023 CAPLUS  
 DN 131:165293  
 TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for  
 treating **hepatitis** virus infections  
 IN Mueller, Richard A.; Bryant, Martin L.; Partis, Richard A.  
 PA G.D. Searle & Co., USA  
 SO PCT Int. Appl., 138 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9940916	A1	19990819	WO 1999-US1874	19990212
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9927595	A1	19990830	AU 1999-27595	19990212
	BR 9907882	A	20001017	BR 1999-7882	19990212
	EP 1061922	A1	20001227	EP 1999-908079	19990212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				

FI  
 PRAI US 1998-23401 A 19980212  
 US 1998-74508 P 19980212  
 WO 1999-US1874 W 19990212

OS MARPAT 131:165293  
 RE.CNT 9  
 RE

- (1) Bayer AG; EP 0449026 A 1991 CAPLUS
- (3) G D Searle & Co; WO 9522975 A 1995 CAPLUS
- (4) G D Searle & Co; EP 0367748 A 1990 CAPLUS
- (5) G D Searle and Co; WO 9835685 A 1998 CAPLUS
- (6) Meiji Seika Kaisha Ltd; EP 0350012 A 1990 CAPLUS

Block, Timothy M.  
CS The Glycobiology Institute, Department of Biochemistry, Oxford  
University,

Oxford, OX1 3QU, UK

SO Proc. Natl. Acad. Sci. U. S. A. (1999), 96(21), 11878-11882

CODEN: PNASA6; ISSN: 0027-8424

PB National Academy of Sciences

DT Journal

LA English

RE.CNT 21

RE

(2) Block, T; Nat Med 1998, V4, P610 CAPLUS

(3) Block, T; Proc Natl Acad Sci USA 1994, V91, P2235 CAPLUS

(4) Chambers, T; Annu Rev Microbiol 1990, V44, P649 CAPLUS

(5) Choukhi, A; J Virol 1998, V72, P3851 CAPLUS

(7) Dubuisson, J; J Virol 1994, V68, P6147 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 1999:529023 CAPLUS

DN 131:165293

TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for  
treating **hepatitis** virus infections

IN Mueller, Richard A.; Bryant, Martin L.; Partis, Richard A.

PA G.D. Searle & Co., USA

SO PCT Int. Appl., 138 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	----	-----	-----
PI	WO 9940916	A1	19990819	WO 1999-US1874	19990212
	W:				
	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				
	DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,				
	KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,				
	MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,				
	TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU,				
	TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,				
	FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,				
	CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9927595	A1	19990830	AU 1999-27595	19990212
	BR 9907882	A	20001017	BR 1999-7882	19990212
	EP 1061922	A1	20001227	EP 1999-908079	19990212
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				

FI

PRAI US 1998-23401 A 19980212

US 1998-74508 P 19980212

WO 1999-US1874 W 19990212

OS MARPAT 131:165293

RE.CNT 9

RE

(1) Bayer AG; EP 0449026 A 1991 CAPLUS

(3) G D Searle & Co; WO 9522975 A 1995 CAPLUS

(4) G D Searle & Co; EP 0367748 A 1990 CAPLUS

(5) G D Searle and Co; WO 9835685 A 1998 CAPLUS

(6) Meiji Seika Kaisha Ltd; EP 0350012 A 1990 CAPLUS

## ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 1999:390377 CAPLUS

DN 131:39716

TI Glucosidase or glucosyltransferase inhibitors for inhibition of  
membrane-associated viral replication and treatment of lipid storage  
diseasesIN Blumberg, Baruch S.; Block, Timothy M.; Dwek, Raymond A.; Mehta, Anand;  
Platt, Frances; Butters, Terry D.; Zitzmann, NicolePA The Chancellor, Masters and Scholars of the University of Oxford, UK;  
Thomas Jefferson University

SO PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9929321	A1	19990617	WO 1998-US26241	19981210
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9917215	A1	19990628	AU 1999-17215	19981210
	EP 1037636	A1	20000927	EP 1998-962046	19981210
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	BR 9813508	A	20001003	BR 1998-13508	19981210
PRAI	US 1997-69245	P	19971211		
	WO 1998-US26241	W	19981210		

OS MARPAT 131:39716

RE.CNT 2

RE

(1) Bryant; US 5622972 A 1997 CAPLUS

(2) Rohrschneider; US 5643888 A 1997 CAPLUS

L11 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 1998:568726 CAPLUS

DN 129:197981

TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in  
combination therapy for treating **hepatitis** virus infections

IN Jacob, Gary S.; Block, Timothy M.; Dwek, Raymond A.

PA G.D. Searle and Co., USA

SO PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9835685	A1	19980820	WO 1998-US3004	19980212
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,			

## ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 1999:390377 CAPLUS

DN 131:39716

TI Glucosidase or glucosyltransferase inhibitors for inhibition of  
membrane-associated viral replication and treatment of lipid storage  
diseasesIN Blumberg, Baruch S.; Block, Timothy M.; Dwek, Raymond A.; Mehta, Anand;  
Platt, Frances; Butters, Terry D.; Zitzmann, NicolePA The Chancellor, Masters and Scholars of the University of Oxford, UK;  
Thomas Jefferson University

SO PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 9929321	A1	19990617	WO 1998-US26241	19981210
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9917215	A1	19990628	AU 1999-17215	19981210
	EP 1037636	A1	20000927	EP 1998-962046	19981210
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	BR 9813508	A	20001003	BR 1998-13508	19981210
PRAI	US 1997-69245	P	19971211		
	WO 1998-US26241	W	19981210		

OS MARPAT 131:39716

RE.CNT 2

RE

(1) Bryant; US 5622972 A 1997 CAPLUS

(2) Rohrschneider; US 5643888 A 1997 CAPLUS

L11 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 1998:568726 CAPLUS

DN 129:197981

TI Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in  
combination therapy for treating **hepatitis** virus infections

IN Jacob, Gary S.; Block, Timothy M.; Dwek, Raymond A.

PA G.D. Searle and Co., USA

SO PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 9835685	A1	19980820	WO 1998-US3004	19980212
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				



DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,  
 LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,  
 PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US,  
 UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,  
 FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,  
 GA, GN, ML, MR, NE, SN, TD, TG  
 AU 9861692 A1 19980908 AU 1998-61692 19980212  
 EP 1007058 A1 20000614 EP 1998-906475 19980212  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,  
 FI  
 JP 2001512462 T2 20010821 JP 1998-535987 19980212  
 PRAI US 1997-41221 P 19970214  
 WO 1998-US3004 W 19980212  
 OS MARPAT 129:197981

L11 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2001 ACS  
 AN 1996:676601 CAPLUS  
 DN 126:166108  
 TI Copper(II) interactions with an experimental antiviral agent,  
 1-deoxynojirimycin, and oxygen activation by resulting complexes  
 AU Jezowska-Bojczuk, Malgorzata; Bal, Wojciech; Kasprzak, Kazimierz S.  
 CS Faculty of Chemistry, University of Wroclaw, Wroclaw, 50-383, Pol.  
 SO J. Inorg. Biochem. (1996), 64(4), 231-246  
 CODEN: JIBIDJ; ISSN: 0162-0134  
 PB Elsevier  
 DT Journal  
 LA English

L11 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2001 ACS  
 AN 1996:385934 CAPLUS  
 DN 125:41767  
 TI Synthesis and formulation of triazine derivatives as **hepatitis**  
 remedies  
 IN Ueda, Fusao; Ozaki, Takayuki; Nakamura, Ken-ichi  
 PA Nippon Shinyaku Co., Ltd., Japan  
 SO PCT Int. Appl., 56 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9604914	A1	19960222	WO 1995-JP1577	19950808
	W: AU, BR, CA, CN, FI, HU, JP, KR, MX, NO, NZ, RU, UA, US, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2197091	AA	19960222	CA 1995-2197091	19950808
	AU 9531920	A1	19960307	AU 1995-31920	19950808
	AU 703263	B2	19990325		
	EP 775487	A1	19970528	EP 1995-927992	19950808
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, PT, SE				
	CN 1155244	A	19970723	CN 1995-194521	19950808
	BR 9508539	A	19971028	BR 1995-8539	19950808
	HU 77735	A2	19980728	HU 1997-355	19950808
	RU 2147233	C1	20000410	RU 1997-103983	19950808
	US 5962453	A	19991005	US 1997-776992	19970206
PRAI	JP 1994-185810	A	19940808		
	WO 1995-JP1577	W	19950808		

DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,  
 LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,  
 PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US,  
 UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,  
 FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,  
 GA, GN, ML, MR, NE, SN, TD, TG  
 AU 9861692 A1 19980908 AU 1998-61692 19980212  
 EP 1007058 A1 20000614 EP 1998-906475 19980212  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,  
 FI JP 2001512462 T2 20010821 JP 1998-535987 19980212  
 PRAI US 1997-41221 P 19970214  
 WO 1998-US3004 W 19980212  
 OS MARPAT 129:197981

L11 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2001 ACS  
 AN 1996:676601 CAPLUS  
 DN 126:166108  
 TI Copper(II) interactions with an experimental antiviral agent,  
 l-deoxynojirimycin, and oxygen activation by resulting complexes  
 AU Jezowska-Bojczuk, Malgorzata; Bal, Wojciech; Kasprzak, Kazimierz S.  
 CS Faculty of Chemistry, University of Wroclaw, Wroclaw, 50-383, Pol.  
 SO J. Inorg. Biochem. (1996), 64(4), 231-246  
 CODEN: JIBIDJ; ISSN: 0162-0134  
 PB Elsevier  
 DT Journal  
 LA English

L11 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2001 ACS  
 AN 1996:385934 CAPLUS  
 DN 125:41767  
 TI Synthesis and formulation of triazine derivatives as **hepatitis**  
 remedies  
 IN Ueda, Fusao; Ozaki, Takayuki; Nakamura, Ken-ichi  
 PA Nippon Shinyaku Co., Ltd., Japan  
 SO PCT Int. Appl., 56 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9604914	A1	19960222	WO 1995-JP1577	19950808
	W: AU, BR, CA, CN, FI, HU, JP, KR, MX, NO, NZ, RU, UA, US, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2197091	AA	19960222	CA 1995-2197091	19950808
	AU 9531920	A1	19960307	AU 1995-31920	19950808
	AU 703263	B2	19990325		
	EP 775487	A1	19970528	EP 1995-927992	19950808
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, PT, SE				
	CN 1155244	A	19970723	CN 1995-194521	19950808
	BR 9508539	A	19971028	BR 1995-8539	19950808
	HU 77735	A2	19980728	HU 1997-355	19950808
	RU 2147233	C1	20000410	RU 1997-103983	19950808
	US 5962453	A	19991005	US 1997-776992	19970206
PRAI	JP 1994-185810	A	19940808		
	WO 1995-JP1577	W	19950808		

OS MARPAT 125:41767

L11 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 1995:785110 CAPLUS

DN 123:160827

TI Use of N-alkyl derivatives of 1,5-dideoxy-1,5-imino-D-glucitol for the treatment of **hepatitis** B virus infections

IN Block, Timothy M.; Blumberg, Baruch S.; Dwek, Raymond A.

PA G.D. Searle and Co., USA; Monsanto Co.

SO PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9519172	A1	19950720	WO 1994-US14548	19941223
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ,				
VN					
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2181033	AA	19950720	CA 1994-2181033	19941223
	AU 9514037	A1	19950801	AU 1995-14037	19941223
	EP 739205	A1	19961030	EP 1995-905416	19941223
	EP 739205	B1	19991124		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1149253	A	19970507	CN 1994-195049	19941223
	JP 09508111	T2	19970819	JP 1994-519024	19941223
	AT 186836	E	19991215	AT 1995-905416	19941223
	ES 2140652	T3	20000301	ES 1995-905416	19941223
	US 6037351	A	20000314	US 1996-676153	19960711
PRAI	US 1994-181519		19940113		
	WO 1994-US14548		19941223		

L11 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 1994:671340 CAPLUS

DN 121:271340

TI N-Butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. Secretion of human **hepatitis** B virus is inhibited by the imino sugar N-butyldeoxynojirimycin

AU Ganem, Bruce

CS Cornell Univ., USA

SO Chemtracts: Org. Chem. (1994), 7(2), 106-7

CODEN: CMOCEI; ISSN: 0895-4445

DT Journal

LA English

L11 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 1994:235511 CAPLUS

DN 120:235511

TI Secretion of human **hepatitis** B virus is inhibited by the imino sugar N-butyldeoxynojirimycin

AU Block, Timothy M.; Lu, Xuanyong; Platt, Frances M.; Foster, Graham R.; Gerlich, Wolfram H.; Blumberg, Baruch S.; Dwek, Raymond A.

CS Jefferson Cancer Inst., Jefferson Med. Coll., Philadelphia, PA, 19107,

USA

OS MARPAT 125:41767

L11 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 1995:785110 CAPLUS

DN 123:160827

TI Use of N-alkyl derivatives of 1,5-dideoxy-1,5-imino-D-glucitol for the treatment of **hepatitis** B virus infections

IN Block, Timothy M.; Blumberg, Baruch S.; Dwek, Raymond A.

PA G.D. Searle and Co., USA; Monsanto Co.

SO PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9519172	A1	19950720	WO 1994-US14548	19941223
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ,				
VN					
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2181033	AA	19950720	CA 1994-2181033	19941223
	AU 9514037	A1	19950801	AU 1995-14037	19941223
	EP 739205	A1	19961030	EP 1995-905416	19941223
	EP 739205	B1	19991124		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1149253	A	19970507	CN 1994-195049	19941223
	JP 09508111	T2	19970819	JP 1994-519024	19941223
	AT 186836	E	19991215	AT 1995-905416	19941223
	ES 2140652	T3	20000301	ES 1995-905416	19941223
	US 6037351	A	20000314	US 1996-676153	19960711
PRAI	US 1994-181519		19940113		
	WO 1994-US14548		19941223		

L11 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 1994:671340 CAPLUS

DN 121:271340

TI N-Butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. Secretion of human **hepatitis** B virus is inhibited by the imino sugar N-butyldeoxynojirimycin

AU Ganem, Bruce

CS Cornell Univ., USA

SO Chemtracts: Org. Chem. (1994), 7(2), 106-7

CODEN: CMOCEI; ISSN: 0895-4445

DT Journal

LA English

L11 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2001 ACS

AN 1994:235511 CAPLUS

DN 120:235511

TI Secretion of human **hepatitis** B virus is inhibited by the imino sugar N-butyldeoxynojirimycin

AU Block, Timothy M.; Lu, Xuanyong; Platt, Frances M.; Foster, Graham R.; Gerlich, Wolfram H.; Blumberg, Baruch S.; Dwek, Raymond A.

CS Jefferson Cancer Inst., Jefferson Med. Coll., Philadelphia, PA, 19107, USA

SO Proc. Natl. Acad. Sci. U. S. A. (1994), 91(6), 2235-9  
CODEN: PNASA6; ISSN: 0027-8424  
DT Journal  
LA English

L11 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2001 ACS  
AN 1985:592966 CAPLUS  
DN 103:192966  
TI The effects of processing inhibitors of N-linked oligosaccharides on the intracellular migration of glycoprotein E2 of mouse **hepatitis** virus and the maturation of coronavirus particles  
AU Repp, Reinald; Tamura, Teruko; Boschek, C. Bruce; Wege, H.; Schwarz, Ralph  
T.; Niemann, Heiner  
CS Inst. Med. Virol., Justus-Liebig-Univ., Giessen, D-6300, Fed. Rep. Ger.  
SO J. Biol. Chem. (1985), 260(29), 15873-9  
CODEN: JBCHA3; ISSN: 0021-9258  
DT Journal  
LA English

=> d l11 16 all

L11 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2001 ACS  
AN 1995:785110 CAPLUS  
DN 123:160827  
TI Use of N-alkyl derivatives of 1,5-dideoxy-1,5-imino-D-glucitol for the treatment of **hepatitis** B virus infections  
IN Block, Timothy M.; Blumberg, Baruch S.; Dwek, Raymond A.  
PA G.D. Searle and Co., USA; Monsanto Co.  
SO PCT Int. Appl., 29 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
IC ICM A61K031-445  
CC 1-5 (Pharmacology)

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 9519172	A1	19950720	WO 1994-US14548	19941223
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ,				
VN	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2181033	AA	19950720	CA 1994-2181033	19941223
	AU 9514037	A1	19950801	AU 1995-14037	19941223
	EP 739205	A1	19961030	EP 1995-905416	19941223
	EP 739205	B1	19991124		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1149253	A	19970507	CN 1994-195049	19941223
	JP 09508111	T2	19970819	JP 1994-519024	19941223
	AT 186836	E	19991215	AT 1995-905416	19941223
	ES 2140652	T3	20000301	ES 1995-905416	19941223
	US 6037351	A	20000314	US 1996-676153	19960711
PRAI	US 1994-181519		19940113		

SO Proc. Natl. Acad. Sci. U. S. A. (1994), 91(6), 2235-9  
 CODEN: PNASA6; ISSN: 0027-8424

DT Journal  
 LA English

L11 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2001 ACS  
 AN 1985:592966 CAPLUS  
 DN 103:192966  
 TI The effects of processing inhibitors of N-linked oligosaccharides on the intracellular migration of glycoprotein E2 of mouse **hepatitis** virus and the maturation of coronavirus particles  
 AU Repp, Reinald; Tamura, Teruko; Boschek, C. Bruce; Wege, H.; Schwarz, Ralph  
 T.; Niemann, Heiner  
 CS Inst. Med. Virol., Justus-Liebig-Univ., Giessen, D-6300, Fed. Rep. Ger.  
 SO J. Biol. Chem. (1985), 260(29), 15873-9  
 CODEN: JBCHA3; ISSN: 0021-9258

DT Journal  
 LA English

=> d l11 16 all

L11 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2001 ACS  
 AN 1995:785110 CAPLUS  
 DN 123:160827  
 TI Use of N-alkyl derivatives of 1,5-dideoxy-1,5-imino-D-glucitol for the treatment of **hepatitis** B virus infections  
 IN Block, Timothy M.; Blumberg, Baruch S.; Dwek, Raymond A.  
 PA G.D. Searle and Co., USA; Monsanto Co.  
 SO PCT Int. Appl., 29 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English  
 IC ICM A61K031-445  
 CC 1-5 (Pharmacology)

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9519172	A1	19950720	WO 1994-US14548	19941223
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ,				
VN	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2181033	AA	19950720	CA 1994-2181033	19941223
	AU 9514037	A1	19950801	AU 1995-14037	19941223
	EP 739205	A1	19961030	EP 1995-905416	19941223
	EP 739205	B1	19991124		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1149253	A	19970507	CN 1994-195049	19941223
	JP 09508111	T2	19970819	JP 1994-519024	19941223
	AT 186836	E	19991215	AT 1995-905416	19941223
	ES 2140652	T3	20000301	ES 1995-905416	19941223
	US 6037351	A	20000314	US 1996-676153	19960711
PRAI	US 1994-181519		19940113		

WO 1994-US14548                      19941223

AB    A method is disclosed for the treatment of **hepatitis B** virus (HBV) infections, which comprises administering to the infected host an N-alkyl deriv. of 1,5-dideoxy-1,5-imido-D-glucitol in which the alkyl group contains from 3 to 6 carbon atoms. In examples, N-butyl-1,5-dideoxy-1,5-imino-D-glucitol was shown to suppress the secretion of HBV particles and to cause intracellular retention of HBV

DNA    in both stably transfected HepG 2.2.15 cells and HBV-infected HepG 2 cells.

ST    deoxynojirimycin deriv virucide **hepatitis B**

IT    Virucides and Virustats  
       (deoxynojirimycin alkyl derivs. for treatment of **hepatitis B** virus infections)

IT    Virus, animal  
       (**hepatitis B**, deoxynojirimycin alkyl derivs. for treatment of **hepatitis B** virus infections)

IT    72599-27-0, N-Butyl 1-deoxynojirimycin  
       RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
       (deoxynojirimycin alkyl derivs. for treatment of **hepatitis B** virus infections)

=> d his

(FILE 'HOME' ENTERED AT 11:59:11 ON 27 SEP 2001)

FILE 'REGISTRY' ENTERED AT 11:59:22 ON 27 SEP 2001

E DEOXYNOJIRIMYCIN

L1                32 S E1-E3

L2                10 S 3TC

FILE 'CAPLUS' ENTERED AT 12:01:58 ON 27 SEP 2001

E HEPATITIS

L3                31704 S E3

L4                4491 S HBV

L5                751 S L1

L6                1070 S L2

L7                16 S L5 AND L6

L8                271 S L6 AND L3

L9                176 S L8 AND L4

L10               160 S L9 AND ANTIVIRAL

L11               19 S L5 AND L3

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

WO 1994-US14548                      19941223

AB    A method is disclosed for the treatment of **hepatitis B** virus (HBV) infections, which comprises administering to the infected host an N-alkyl deriv. of 1,5-dideoxy-1,5-imido-D-glucitol in which the alkyl group contains from 3 to 6 carbon atoms. In examples, N-butyl-1,5-dideoxy-1,5-imino-D-glucitol was shown to suppress the secretion of HBV particles and to cause intracellular retention of HBV

DNA    in both stably transfected HepG 2.2.15 cells and HBV-infected HepG 2 cells.

ST    deoxynojirimycin deriv virucide **hepatitis B**

IT    Virucides and Virustats  
       (deoxynojirimycin alkyl derivs. for treatment of **hepatitis B** virus infections)

IT    Virus, animal  
       (**hepatitis B**, deoxynojirimycin alkyl derivs. for treatment of **hepatitis B** virus infections)

IT    **72599-27-0**, N-Butyl 1-deoxynojirimycin  
       RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
       (deoxynojirimycin alkyl derivs. for treatment of **hepatitis B** virus infections)

=> d his

(FILE 'HOME' ENTERED AT 11:59:11 ON 27 SEP 2001)

FILE 'REGISTRY' ENTERED AT 11:59:22 ON 27 SEP 2001

E DEOXYNOJIRIMYCIN

L1            32 S E1-E3

L2            10 S 3TC

FILE 'CAPLUS' ENTERED AT 12:01:58 ON 27 SEP 2001

E HEPATITIS

L3            31704 S E3

L4            4491 S HBV

L5            751 S L1

L6            1070 S L2

L7            16 S L5 AND L6

L8            271 S L6 AND L3

L9            176 S L8 AND L4

L10           160 S L9 AND ANTIVIRAL

L11           19 S L5 AND L3

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL



FULL ESTIMATED COST	ENTRY 98.29	SESSION 119.38
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.35	-2.35

\*\*\*\*\*

Dear valued customer,

Your feedback is important to us. Would you kindly take a moment to complete our survey? This survey will only take about 5-10 minutes to complete. Your responses will be kept confidential and will help us improve STN Express with Discover! for your future use. Please click on the following link to access the survey.

<http://www.cas.org/ONLINE/STN/ExpressSurveyForm.html?LOGINID=SSSPTAU125RXT>

\*\*\*\*\*

STN INTERNATIONAL LOGOFF AT 12:13:32 ON 27 SEP 2001

FULL ESTIMATED COST	ENTRY	SESSION
	98.29	119.38
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-2.35	-2.35

\*\*\*\*\*

Dear valued customer,

Your feedback is important to us. Would you kindly take a moment to complete our survey? This survey will only take about 5-10 minutes to complete. Your responses will be kept confidential and will help us improve STN Express with Discover! for your future use. Please click on the following link to access the survey.

<http://www.cas.org/ONLINE/STN/ExpressSurveyForm.html?LOGINID=SSSPTAU125RXT>

\*\*\*\*\*

STN INTERNATIONAL LOGOFF AT 12:13:32 ON 27 SEP 2001